Pyrimidines for degrading bruton's tyrosine kinase
Compounds that induce Btk degradation through ubiquitin proteolytic pathway, bind Btk and recruit ubiquitin ligase, solve the problem of difficulty in effectively degrading Btk in the prior art, and provide a new method for treating CLL, affecting B cell signaling Conducting path.
Patent Information
- Application Number
- CN202380027808.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-22
- Filing Date
- 2023-03-21
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to effectively degrade Bruton's tyrosine kinase (Btk), affects B cell function, and lacks effective Btk inhibitors.
Provided is a compound that induces Btk degradation through the ubiquitin proteolytic pathway. The specific compound formula (I) promotes ubiquitination and degradation of Btk by binding to Btk and recruiting ubiquitin ligase, thereby reducing the amount of Btk in cells.
Effectively degrade Btk, potentially used to treat diseases such as chronic lymphocytic leukemia (CLL), and by reducing the expression of Btk protein, it affects the B cell signaling pathway, providing an alternative Btk inhibitor regimen.
Smart Images

Figure CN119072475A_ABST
Abstract
Description
Background Art
[0001] Bruton's tyrosine kinase (Btk) is a key signal transduction enzyme expressed in hematopoietic cell types. Btk plays an important role in the B cell signal transduction pathway that links cell surface B cell receptor (BCR) stimulation with downstream intracellular responses. Btk is a key regulator of B cell development, activation, signal transduction and survival (Kurosaki, Curr Op Imm, 2000, 276-281; Schaeffer and Schwartzberg, Curr Op Imm 2000, 282-288). In addition, Btk plays a role in other hematopoietic cell signal transduction pathways, such as Toll-like receptors (TLR) and cytokine receptor-mediated TNF-α production in macrophages, IgE receptor (FcepsilonRI) signal transduction in mast cells, inhibition of Fas / APO-1 apoptosis signal transduction in B lymphocytes, and collagen-stimulated platelet aggregation. See, for example, CA Jeffries et al., (2003), Journal of Biological Chemistry 278: 26258-26264; NJ Horwood et al., (2003), The Journal of Experimental Medicine 197: 1603-1611; Iwaki et al., (2005), Journal of Biological Chemistry 280 (48): 40261-40270; Vassilev et al., (1999), Journal of Biological Chemistry 274 (3): 1646-1656; and Quek et al., (1998), Current Biology 8 (20): 1137-1140. Currently, Btk inhibitors are being studied. As an alternative to inhibition, proteolytic degradation of Btk can affect B cell function not only by blocking BCR signaling, but also by reducing the presence of Btk protein from the cell itself. Reduction of Btk protein will reduce Btk kinase activity as well as reduce any protein interaction or scaffolding function of Btk. Therefore, there is a medical need to develop Btk degraders. Summary of the invention
[0002] In certain embodiments, provided herein are compounds that induce proteolytic degradation of Btk via the ubiquitin proteolytic pathway.
[0003] In certain embodiments, a compound of formula (I) is provided,
[0004]
[0005] in
[0006] R 1 is selected from the group consisting of hydrogen, C1-C3 alkyl, CN, C1-C3 haloalkyl, halogen, CH2OCH3, CH2OH and CH2CN;
[0007] R 2 and R 3 each independently selected from the group consisting of: hydrogen and halogen;
[0008] R 4a and R 4b are each independently selected from the group consisting of hydrogen, C1-C3 alkyl, and CH2OCH3; and
[0009] R 5 is selected from the group consisting of hydrogen, halogen and C1-C3 alkyl;
[0010] or a pharmaceutically acceptable salt thereof.
[0011] In certain embodiments, R 1 is selected from the group consisting of hydrogen, C1-C3 alkyl, CN (cyano), C1-C3 haloalkyl, halogen, CH2OCH3, CH2OH, and CH2CN, or a pharmaceutically acceptable salt thereof. 1 is C1-C3 alkyl or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is hydrogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is CN or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is C1-C3 haloalkyl or a pharmaceutically acceptable salt thereof. 1 is CF3 or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is a halogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is Cl or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is F or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is CH2OCH3 or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is CH2OH or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is CH2CN or a pharmaceutically acceptable salt thereof.
[0012] In certain embodiments, R 2 is selected from the group consisting of hydrogen and halogen, or a pharmaceutically acceptable salt thereof. 2 is hydrogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 2 is a halogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 2 is F or a pharmaceutically acceptable salt thereof.
[0013] In certain embodiments, R 3 is selected from the group consisting of hydrogen and halogen, or a pharmaceutically acceptable salt thereof. 3 is hydrogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 3 is a halogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 3 is F or a pharmaceutically acceptable salt thereof.
[0014] In certain embodiments, R 4a and R 4b Each is independently selected from the group consisting of hydrogen, C1-C3 alkyl and CH2OCH3, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is hydrogen and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is hydrogen and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is methyl and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is hydrogen and R 4b is ethyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is ethyl and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is methyl and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is hydrogen and R 4b is isopropyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is isopropyl and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is hydrogen and R 4b is CH2OCH3, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 4a is CH2OCH3 and R4b is hydrogen, or a pharmaceutically acceptable salt thereof.
[0015] In certain embodiments, R 5 is selected from the group consisting of hydrogen, halogen and C1-C3 alkyl, or a pharmaceutically acceptable salt thereof. 5 is hydrogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is a halogen or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is F or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is Cl or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is methyl or a pharmaceutically acceptable salt thereof.
[0016] In certain embodiments, R 1 is methyl and R 2 is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl, R 2 is hydrogen, R 3 is hydrogen, R 4a is hydrogen, and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl, R 2 is hydrogen, R 3 is hydrogen, and R 5 is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl, R 4a is hydrogen, and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 2 is hydrogen, R 4a is hydrogen, and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 3 is hydrogen, R 4a is hydrogen, and R 4b is methyl, or a pharmaceutically acceptable salt thereof.
[0017] In certain embodiments, R 5 is hydrogen, R 4a is hydrogen, and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is hydrogen, R4a is hydrogen, R 4b is a methyl group, and R 3 is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is hydrogen, R 4a is hydrogen, R 4b is a methyl group, and R 3 is hydrogen and R 2 is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is hydrogen, R 4a is hydrogen, R 4b is methyl, R 3 is hydrogen, and R 1 is methyl, or a pharmaceutically acceptable salt thereof.
[0018] In certain embodiments, R 1 is methyl and R 3 is a halogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl and R 3 is F, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl and R 2 is a halogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 1 is methyl and R 2 is F, or a pharmaceutically acceptable salt thereof.
[0019] In certain embodiments, R 5 is a halogen, R 4a is hydrogen, and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 It's F, R 4a is hydrogen, and R 4b is methyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is a halogen, R 4a is a methyl group, and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 It's F, R 4a is a methyl group, and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is a halogen, R 4a is hydrogen, and R 4b is ethyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 It's F, R 4a is hydrogen, and R 4bis ethyl, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 is a halogen, R 4a is ethyl, and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof. In certain embodiments, R 5 It's F, R 4a is ethyl, and R 4b is hydrogen, or a pharmaceutically acceptable salt thereof.
[0020] In certain embodiments, a pharmaceutical composition is provided, comprising a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
[0021] In certain embodiments, a pharmaceutical composition is provided, comprising a therapeutically effective amount of:
[0022] or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
[0023] In certain embodiments, the compound is:
[0024] or a pharmaceutically acceptable salt thereof.
[0025] In certain embodiments, the compound is:
[0026]
[0027] In certain embodiments, the compound is a pharmaceutically acceptable salt of:
[0028]
[0029] In certain embodiments, the compound is 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
[0030] In certain embodiments, the compound is 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide.
[0031] In certain embodiments, the compound is a pharmaceutically acceptable salt of: In certain embodiments, the compound is 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide.
[0032] In certain embodiments, the compound is selected from the group consisting of:
[0033] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0034] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0035] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide;
[0036] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)-3-fluorophenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0037] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)-3-fluorophenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0038] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0039] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)-3-fluorophenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0040] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0041] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2,2-dimethylpiperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide;
[0042] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-3-fluoro-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0043] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-3-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide;
[0044] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-5-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide;
[0045] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-(propan-2-yl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0046] 3-tert-butyl-N-[(1R)-1-{2-chloro-4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]phenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0047] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-(methoxymethyl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide;
[0048] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-(trifluoromethyl)phenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; and
[0049] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-fluorophenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; or a pharmaceutically acceptable salt thereof.
[0050] Definition of terms
[0051] As used in the specification and appended claims, the following terms have the indicated meanings unless indicated to the contrary.
[0052] Note that, as used in this specification and the intended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a compound" includes a single compound as well as one or more identical or different compounds.
[0053] In some cases, the number of carbon atoms in a moiety is indicated by the prefix "C x -C y ” means, where x is the minimum number of carbon atoms in the substituent and y is the maximum number of carbon atoms. Thus, for example, “C1-C3 alkyl” means an alkyl substituent containing from 1 to 3 carbon atoms.
[0054] Unless otherwise indicated, as used herein, the term "alkyl" refers to a saturated straight or branched hydrocarbon chain radical having one, two, three, four, five, or six carbon atoms. The term "C1-C3 alkyl" refers to an alkyl having one, two, or three carbon atoms. Examples of alkyls include, but are not limited to, methyl, ethyl, propyl, isopropyl, and the like. In certain embodiments, the alkyl is methyl. In certain embodiments, the alkyl is ethyl. In certain embodiments, the alkyl is propyl. In certain embodiments, the alkyl is isopropyl.
[0055] As used herein, the term "halogen" means Cl (chlorine), Br (bromine), I (iodine) and F (fluorine). In certain embodiments, the halogen is selected from the group consisting of Cl or F. In certain embodiments, the halogen is Cl. In certain embodiments, the halogen is F.
[0056] As used herein, the term "haloalkyl" refers to an alkyl group as defined herein, wherein one or more hydrogen atoms are replaced by a halogen group. 1- "C3 haloalkyl" refers to a haloalkyl group having one, two, or three carbon atoms. In certain embodiments, one, two, or three hydrogen atoms may each be replaced by a fluoro group. Examples of haloalkyl groups are trifluoromethyl or CF3. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] FIG1 shows that compound 1 (Example 1) has Btk in C57BL / 6 mice C481S In vivo activity in mutant TCL1-driven CLL. DETAILED DESCRIPTION
[0058] In certain embodiments, the compounds disclosed herein include two ligands connected via a linker. The first ligand can bind to Btk. The second ligand can recruit ubiquitin ligases. In certain embodiments, the ubiquitin ligase is an E3 ligase. In certain embodiments, the E3 ubiquitin ligase is cereblon (CRBN) and / or comprises cereblon (CRBN). In certain embodiments, the second ligand can recruit CRBN. In certain embodiments, the compounds described herein can bind to Btk and can recruit ubiquitin ligases comprising cereblon. In certain embodiments, the compounds disclosed herein recruit E3 ligases to Btk and cause neighbor-induced ubiquitination and degradation of Btk through the ubiquitin proteasome system (UPS). In certain embodiments, the compounds disclosed herein can bind to Btk and reduce the amount of Btk in cells via degradation.
[0059] In certain embodiments, the compounds disclosed herein can be used to treat chronic lymphocytic leukemia (CLL). For example, the compounds described herein can be used to treat CLL by degrading the patient's Btk via the ubiquitin proteolytic pathway.
[0060] In certain embodiments, the compounds disclosed herein degrade Btk C481S Btk in cell lines C481S Protein (Btk protein with C481 mutation).
[0061] In certain embodiments, a method of treating a patient suffering from CLL is provided, the method comprising administering to the patient a compound of Formula (I).
[0062] In certain embodiments, a method for treating CLL is provided, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I).
[0063] The phrase "pharmaceutically acceptable salts" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio.
[0064] As used herein, the term "subject" refers to a human. The terms "human," "patient," and "subject" are used interchangeably herein.
[0065] As used herein, the term "treatment" refers to a method of alleviating or eliminating a disease and / or its attendant symptoms.
[0066] The phrase "therapeutically effective amount" refers to an amount of a compound or a pharmaceutically acceptable salt thereof that, when administered for treatment in a particular subject or subject population, is sufficient to prevent the manifestation of the condition or disorder being treated or to alleviate to some extent one or more symptoms of the condition or disorder being treated. In certain embodiments, this amount is effective to degrade Btk in the patient.
[0067] Universal synthesis
[0068] The compounds of the present disclosure may be better understood in conjunction with the following synthetic schemes and methods that illustrate means by which the compounds may be prepared. Representative procedures are shown, but are not limited to, in Schemes 1-5. In Schemes 1-5, variable R 1 , R 2 , R 3 , R 4 and R 5 The final compounds of the present invention can be prepared by using the ACD / Name 2021.1.3 (file version N15E41, Build 123232, July 7, 2021) software program and / or by using as The intermediate uses the Struct=Name naming algorithm of part of Professionalv.20.1.1.125. Professional v.20.1.1.125.
[0069] The compounds of the present invention can be prepared according to the schemes outlined below.
[0070] Solution 1
[0071]
[0072] The method for preparing substituted 1-phenyldihydropyrimidine-2,4(1H,3H)-dione building blocks 1-6 is illustrated in Scheme 1. The substituent group R on compound 1-1 5 Can be halogen, hydrogen or C1-C3 alkyl, as described herein. The reaction of compound 1-1 with tert-butyldimethylsilyl chloride in the presence of imidazole can give compound 1-2. Compound 1-2 can be reacted with acrylic acid using heating to form compound 1-3. Compound 1-3 can be reacted with urea in heated acetic acid to produce compound 1-4. Compound 1-4 can be treated with aqueous HCl to give intermediate 1-5. Intermediate 1-5 can be treated with iodine in the presence of imidazole and then treated with Ph3P to give iodo compound 1-6, or it can be treated with CBr4 and then treated with Ph3P to give bromo compound 1-6.
[0073] Solution 2
[0074]
[0075] A method for preparing substituted building blocks 2-7 is illustrated in Scheme 2. Substituted benzaldehyde 2-1 (where R 1 , R 2 and R 3 Compound 2-3 can be obtained by reaction of (S)-2-methylpropane-2-sulfinamide 2-2 as described herein. Compound 2-3 can be reacted with CHMgBr under Grignard reaction conditions to give intermediate 2-4. Intermediate 2-5 can be synthesized from intermediate 2-4 using bis(pinacolato)diboron and a palladium catalyst. Amine 2-6 can be prepared from intermediate 2-5 by removing the tert-butylsulfinyl group using a strong acid or iodine. Heteroarylcarboxamide building blocks 2-7 can be directly synthesized from amine 2-6 and methyl 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylate.
[0076] Solution 3
[0077]
[0078] As shown in Scheme 3, structural unit 3-4 (where R 4a and R 4b As described herein) can be prepared from compound 3-3 by hydrogenation or nitro reduction reaction. Intermediate compound 3-3 can be prepared from 2-nitro-5-halopyridine compound 3-1 and substituted piperazine compound 3-2 by S N Ar reaction or Buchwald-Hartwing cross-coupling reaction.
[0079] Solution 4
[0080]
[0081] The general synthesis of intermediates of formula 4-5 is shown in Scheme 4, where R 1 , R 2 , R 3 , R 4a and R 4b As described herein. Intermediate 4-2 can be prepared by Suzuki reaction of building block 2-7 with 4,6-dichloropyrimidine 4-1. Intermediate 4-4 can be prepared from compound 4-2 via Buchwald-Hartwing cross coupling reaction with substituted 2-aminopyridine compound 3-4. The tert-butoxycarbonyl protecting group can be cleaved with hydrochloric acid or trifluoroacetic acid to give building block 4-5.
[0082] Solution 5
[0083]
[0084] The general synthesis of the target compound of formula 5-4 is shown in Scheme 5, wherein R 1 , R 2 , R 3 , R 4a , R 4b and R 5 The iodo or bromo building blocks 1-6 can be reacted with intermediate 4-5 via an alkylation reaction using sodium iodide and a base such as N,N-diisopropylethylamine to give the target compound 5-4.
[0085] It should be understood that the synthetic schemes and specific examples as shown in the Examples section are illustrative and should not be construed as limiting the scope of the present disclosure, which is defined in the appended claims. All alternatives, modifications and equivalents of the synthetic methods and specific examples are included within the scope of the claims.
[0086] The following examples may be used for illustrative purposes and should not be considered to narrow the scope of the present disclosure.
[0087] Exemplary compounds of formula (I) include, but are not limited to, the compounds shown in Table 1 below and pharmaceutically acceptable salts thereof.
[0088] Table 1. Exemplary compounds
[0089]
[0090]
[0091]
[0092]
[0093] Example
[0094]
[0095]
[0096]
[0097] Final compounds obtained by preparative HPLC can be concentrated by lyophilization. Final examples are typically purified to > 95% purity as determined by HPLC and LCMS at 254 nm. 1 HNMR spectroscopy at Bruker Avance TMIII400MHz NMR spectrometer or Bruker Ascend TM Recorded on a 500 MHz NMR spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) relative to residual undeuterated solvent as an internal reference.
[0098] Example 1
[0099] 3-tert-Butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide
[0100] Example 1A
[0101] (S,E)-N-(4-Bromo-2-methylbenzylidene)-2-methylpropane-2-sulfenamide
[0102] Into a 5L reactor, triisopropyl borate (1.50L, 6.53mol), 4-bromo-2-methylbenzaldehyde (1.00kg, 5.02mol) and (S)-2-methylpropane-2-sulfinamide (669g, 5.53mol) were loaded at ambient temperature. The mixture was stirred at 80°C for about 12 hours. The reaction was repeated twice on the same scale. Water (10.0L) was added to the three batches of reaction mixture combined, and the mixture was extracted with ethyl acetate (4.0L×2), washed with brine (5.0L), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was ground in petroleum ether (5.0L) for 2 hours and filtered. The filter cake was washed with petroleum ether, and the filter cake was dried under reduced pressure to obtain the title compound. 1 H NMR (400MHz, CDCl3): δppm 8.79 (s, 1H), 7.77 (d, J = 6.4Hz, 1H), 7.44 (s, 1H), 7.43 (d, J = 6.4Hz, 1H), 2.59 (s, 3H), 1.27 (s, 9H) ppm.
[0103] Example 1B
[0104] (S)-N-((R)-1-(4-bromo-2-methylphenyl)ethyl)-2-methylpropane-2-sulfenamide
[0105] Dichloromethane (20.0L) and Example 1A (1.00kg, 3.31mol) were loaded into a 50L reactor. The mixture was refrigerated at -20°C. CH3MgBr (3.0M, 1.65L, 4.96mol in tetrahydrofuran) was added dropwise at -20°C. The mixture was then stirred for 16 hours at ambient temperature. The reaction mixture was refrigerated in an ice bath, and saturated aqueous NH4Cl solution (5.0L) was added thereto. The organic phase was separated, and the aqueous phase was extracted with dichloromethane (3.0L×2). The combined organic phases were washed with brine (5.0L), dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the residue was ground in petroleum ether. The crude material was separated by filtration, washed with petroleum ether, and dried under reduced pressure. The same reaction was repeated five times to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.38-7.31 (m, 3H), 5.33 (d, J = 5.2 Hz, 1H), 4.55 (m, 1H), 2.30 (s, 3H), 1.40 (d, J = 5.2 Hz, 1H), 1.08 (s, 9H) ppm. MS (ESI) m / z 318.0, 320.0 (M+H) + .
[0106] Example 1C
[0107] (S)-2-methyl-N-((R)-1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- 1-(4 ...2-(4-phenyl)propane)ethyl)propane-2-sulfenamide
[0108] Into a 5L reaction vessel was charged Example 1B (600 g, 1.89 mol), dioxane (3.6 L), bis(pinacolato)diboron (600 g, 2.36 mol), potassium acetate (370 g, 3.77 moles) and Pd(dppf)Cl2 ([1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), 23.0 g, 0.07 mol) at room temperature. The mixture was degassed with nitrogen and stirred at 85°C for 8 hours under nitrogen. The same reaction was repeated four times on the same scale. The combined five batches of reaction mixture were filtered through diatomaceous earth, and the filter cake was washed with ethyl acetate (0.5 L x 3). The filtrate was concentrated under reduced pressure, and the residue was subjected to silica gel flash column chromatography using petroleum ether and ethyl acetate to obtain the title compound. 1 H NMR (400MHz, CDCl3): δppm 7.58-7.38(m,3H),5.31(d,J=4.8Hz,1H),4.60(m,1H),2.31(s,3H),1.40(d,J=6.8Hz,1H),1.27(s,12H),1.08(s,9H)ppm. MS(ESI)m / z366.2(M+H) + .
[0109] Example 1D
[0110] (R)-1-(2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylamine
[0111] Into a 3 L reactor was charged Example 1C (250 g, 680 mmol) and ethyl acetate (750 mL) at 20°C. The mixture was refrigerated to 0°C. Hydrogen chloride in ethyl acetate (4 M, 750 mL) was added to the mixture at 0°C. The reaction mixture was stirred at 20°C for 2 hours. The mixture was filtered and the solid product was ground in ethyl acetate, filtered and dried under reduced pressure to give the crude title compound as the hydrochloride salt. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): 8.62 (br s, 3H), 7.52-7.60 (m, 3H), 4.51-4.54 (brd, J = 5.2 Hz, 1H), 2.35 (s, 3H), 1.46 (d, J = 6.8 Hz, 3H), 1.28 (s, 12H) ppm. MS (ESI) m / z 262.1 (M+H) + .
[0112] Example 1E
[0113] (R)-3-(tert-butyl)-N-(1-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- (2-(4-(2-(4-(2-(4-(2-(phenyl)-1-yl)-2-(ethyl)-1-(2-(4 ...
[0114] Triethylamine (64.0mL, 459mmol) was added to a solution of Example 1D (20g, 77mmol) and 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid methyl ester (31.0g, 168mmol) in ethanol (200mL) at 20°C. The mixture was stirred at 65°C for 16 hours, and then concentrated under reduced pressure to remove ethanol. Water was added to the mixture, and the mixture was extracted with ethyl acetate (three times). The combined organic layer was washed with saturated aqueous ammonium chloride solution (once) and brine (once), dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain crude material. The crude material was purified by silica gel column chromatography, eluted with petroleum ether and ethyl acetate to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.83 (d, J = 7.7 Hz, 1H), 7.53-7.43 (m, 3H), 5.28 (quin, J = 7.1 Hz, 1H), 2.37 (s, 3H), 1.45 (d, J = 7.0 Hz, 3H), 1.35 (s, 9H), 1.27 (s, 12H) ppm. MS (ESI) m / z 414.3 (M+H) + .
[0115] Example 1F
[0116] 4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)aniline
[0117] A 3 L reactor was charged with 2-(4-aminophenyl)ethan-1-ol (176 g, 1.28 mol), N,N-dimethylformamide (1.8 L), imidazole (91.7 g, 1.35 mol) and tert-butyldimethylsilyl chloride (222 g, 1.48 mol) at ambient temperature. The mixture was stirred at ambient temperature for 6 hours. Ethyl acetate (500 mL) and water (300 mL) were added to the mixture. The organic phase was separated, washed with brine (300 mL), dried over sodium sulfate, concentrated under reduced pressure, and the residue was subjected to flash column chromatography (eluted with petroleum ether and ethyl acetate) to obtain the title compound. MS (ESI) m / z 252.2 (M+H) + .
[0118] Example 1G
[0119] 3-((4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)phenyl)amino)propanoic acid
[0120] Example 1F (196 g, 0.78 mol) was charged into a 3 L reactor. Toluene (1.4 L) and acrylic acid (67.4 g, 0.94 mol) were added to the mixture. The reaction mixture was stirred at 110 °C for 12 hours under nitrogen. The mixture was concentrated to dryness under reduced pressure to give the crude title compound. MS (ESI) m / z 324.2 (M+H) + .
[0121] Example 1H
[0122] 4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)acetic acid phenethyl ester
[0123] To the crude Example 1G (252 g, 0.78 mol) was added acetic acid (1.8 L) and urea (46.8 g, 0.78 mol). The reaction mixture was stirred at 110 °C under nitrogen for 12 hours and cooled to ambient temperature. Water (600 mL) and ethyl acetate (600 mL) were added to the mixture. The organic phase was separated and the aqueous phase was extracted with ethyl acetate (600 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to give the crude title compound. MS (ESI) m / z 277.1 (M+H) + .
[0124] Example II
[0125] 1-(4-(2-Hydroxyethyl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione
[0126] To the crude Example 1H (176 g, 0.63 mol) was added 6N aqueous HCl (1.23 L, 7.39 mol) and the mixture was stirred at ambient temperature for 6 hours. The reaction mixture was concentrated to dryness under reduced pressure and the residue was triturated with ethanol / ethyl acetate (250 mL / 250 mL) for 30 minutes. The material was isolated by filtration and dried in vacuo to give the crude title compound. MS (ESI) m / z 235.1 (M+H) + .
[0127] Example 1J
[0128] 1-(4-(2-iodoethyl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione
[0129] Into 250mL flask, load embodiment II (10.0g, 0.04mol) and dichloromethane (100mL).In ice bath, add iodine (16.3g, 0.06mol) in small portion, then add Ph3P (16.8g, 0.06mol) in small portion, then add imidazole (4.36g, 0.06mol) in small portion.Then the reaction mixture is stirred at ambient temperature for 3 hours.The same reaction is repeated seven times in parallel on the same scale.Eight batches of reaction mixtures are merged, and poured into a mixture of water (800mL) and ethyl acetate (800mL).After vigorous stirring, the organic phase is separated, filtered, dried over sodium sulfate and filtered.The filtrate is concentrated under reduced pressure to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.34 (s, 1H), 7.32-7.24 (m, 4H), 3.75 (m, 2H), 3.49 (m, 2H), 3.13 (m, 2H), 2.72 (m, 2H) ppm. MS (ESI) m / z 345.0 (M+H) + .
[0130] Example 1K
[0131] (S)-tert-Butyl 3-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0132] At 20 ° C, to a solution of 5-chloro-2-nitropyridine (30g, 189mmol) in toluene (600mL), (S)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (37.9g, 189mmol), potassium phosphate (60.2g, 284mmol) and (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (5.89g, 9.46mmol) were added. The reaction vessel was evacuated and backfilled with argon three times, and palladium acetate (II) (2.124g, 9.46mmol) was added at a time at 20 ° C. The container was then evacuated and backfilled with argon three times again. The reaction mixture was warmed to 90 ° C and stirred at 90 ° C for 24 hours under an argon atmosphere. The reaction mixture was cooled, filtered through a diatomaceous earth pad, and washed with ethyl acetate. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel flash column (eluting with 0% to 50% tetrahydrofuran in petroleum ether) to give the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 8.11-8.26 (m, 2H), 7.42 (dd, J = 9.38, 3.00 Hz, 1H), 4.32 (br s, 1H), 3.93 (brs, 1H), 3.79 (brd, J = 12.76 Hz, 2H), 3.14-3.29 (m, 2H), 3.06 (br s, 1H), 1.42 (s, 9H), 1.08 (d, J = 6.63 Hz, 3H) ppm. MS (ESI) m / z 323.2 (M+H) + .
[0133] Example 1L
[0134] (S)-tert-Butyl 4-(6-aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate
[0135] To a suspension of Pd / C (10 wt %, 46.2 g, 43.4 mmol) in tetrahydrofuran (700 mL) was added Example 1K (70 g, 217 mmol), and the reaction mixture was stirred at ambient temperature for 24 hours under hydrogen (15 psi). The same reaction was repeated on the same scale. The combined reaction mixture was filtered through a diatomaceous earth pad, and the filtrate was concentrated under reduced pressure to obtain a crude product. The material was ground with petroleum ether and ethyl acetate, the resulting solid was filtered, and the filter cake was vacuum dried to obtain the title compound. 1HNMR (400MHz, CDCl3): δppm7.62(d,J=2.63Hz,1H),7.20(dd,J=8.76,2.63Hz,1H),6.40(d,J=8.76Hz,1H),5.56(s,2H),3.55(br d,J=11.38Hz,1H),3.39(brd,J=5.13Hz,2H),3.17(br s,2H),2.71-2.90(m,2H),1.41(s,9H),0.75(d,J=6.25Hz,3H)ppm. MS(ESI)m / z 293.2(M+H) + .
[0136] Example 1M
[0137] (R)-3-(tert-butyl)-N-(1-(4-(6-chloropyrimidin-4-yl)-2-methylphenyl)ethyl)-1,2,4-oxadiazole- 5-Formamide
[0138] To a mixture of Example 1E (10 g, 24.19 mmol) and 4,6-dichloropyrimidine (7.21 g, 48.4 mmol) in tetrahydrofuran (400 mL) was added a solution of potassium phosphate (10.27 g, 48.4 mmol) in water (100 mL) at 20°C. The mixture was degassed using a stream of nitrogen at ambient temperature, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.885 g, 1.210 mmol) was added to the mixture under N2. The reaction mixture was heated to 80°C and stirred for 2 hours. The mixture was cooled, poured into water and extracted three times with ethyl acetate. The combined organic layers were washed with brine,
[0139] Dried over sodium sulfate and filtered.The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with tetrahydrofuran in petroleum ether to give the crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.93 (d, J = 7.8 Hz, 1H), 9.07 (s, 1H), 8.30 (s, 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 5.33 (quin, J = 7.2 Hz, 1H), 2.48-2.47 (m, 1H), 2.47 (s, 2H), 1.50 (d, J = 7.0 Hz, 3H), 1.36 (s, 9H) ppm. MS (ESI) m / z 400.1 (M+H) + .
[0140] Example 1N
[0141] (S)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methyl tert-butyl ester
[0142] To a solution of Example 1L (25 g, 86 mmol) in 1,4-dioxane (500 mL) was added Example 1M (34.2 g, 86 mmol), Cs2CO3 (55.7 g, 171 mmol) and (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (4.95 g, 8.55 mmol) at 20°C. The reaction vessel was evacuated and backfilled with argon, and the process was repeated three times. (Tris(dibenzylidene-acetone)dipalladium(0)) (3.91 g, 4.28 mmol) was then added under argon. The reaction vessel was evacuated and backfilled with argon, and the process was repeated three times. The reaction mixture was heated to 100°C and stirred at 100°C for 16 hours. The reaction mixture was cooled, filtered through a diatomaceous earth pad, and washed with ethyl acetate. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluting with tetrahydrofuran in petroleum ether to obtain the title compound. 1 H NMR (400MHz, dimethyl sulfoxide-d6): δppm 10.02(s,1H),9.89(d,J=7.88Hz,1H),8.71(d,J=0.75Hz,1H),7.97-8.10(m,2H),7.79-7.88(m,2H),7.71(brd,J=8.50 Hz,1H),7.61(d,J=8.63Hz,1H),7.44(dd,J=9.13,2.88Hz,1H),5.33(quin,J=7.13Hz,1H),3.73-3.92(m,2H),3.60(br d,J=11.51Hz,1H),3.31(br s,1H),3.16(br d,J=11.88Hz,2H),2.88-3.01(m,1H),2.47(s,3H),1.51(d,J=6.88Hz,3H),1.42(s,9H),1.36(s,9H),0.88(d,J=6.38Hz,3H)ppm. MS(ESI)m / z 656.2(M+H) + .
[0143] Embodiment 10
[0144] 3-(tert-butyl)-N-((R)-1-(2-methyl-4-(6-((5-((S)-2-methylpiperazin-1-yl)pyridin-2-yl) (amino)pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0145] Hydrochloric acid (4N in dioxane, 300mL) was added dropwise to a solution of Example 1N (32g, 48.8mmol) in dioxane (300mL). The reaction mixture was stirred for 2 hours at ambient temperature. The reaction mixture was filtered to separate the crude material, which was dried in vacuo. The crude material was diluted with water (300mL), and a saturated aqueous sodium bicarbonate solution was added to the mixture to adjust the pH to 8. The mixture was extracted with ethyl acetate (twice), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.00 (s, 1H), 9.88 (d, J = 7.78 Hz, 1H), 8.70 (d, J = 0.88 Hz, 1H), 8.04 (br s, 1H), 8.00 (d, J = 2.89 Hz, 1H), 7.79-7.89 (m, 2H), 7.71 (br d,J=8.66Hz,1H),7.61(d,J=8.66Hz,1H)7.43(dd,J=9.16,2.89Hz,1H)5.33(quin,J=7.12Hz,1H)3.67-3.81(m,2H),3.67-3.81(m,1H),3.67-3.8 1(m,1H),3.08-3.17(m,1H),2.89-3.06(m,3H),2.74-2.89(m,2H),2.47 (s, 3H), 1.51 (d, J = 7.03Hz, 3H), 1.36 (s, 9H), 0.96 (d, J = 6.53Hz, 3H) ppm. MS(ESI)m / z 556.2(M+H) + .
[0146] Example 1P
[0147] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4- Oxadiazole-5-carboxamide
[0148] To a solution of Example 10 (24.7 g, 44.5 mmol) in acetonitrile (500 mL) was added Example 1J (18.36 g, 53.3 mmol), N,N-diisopropylethylamine (46.6 mL, 267 mmol) and sodium iodide (19.99 g, 133 mmol) at 20°C. The reaction mixture was stirred at 90°C for 16 hours. The reaction mixture was cooled, poured into an ice bath, and filtered. The filter cake was triturated with ethyl acetate / tetrahydrofuran (twice). The material was dried under reduced pressure to give the title compound. 1H NMR (400MHz, dimethyl sulfoxide-d6): δppm 10.33(s,1H),9.99(s,1H),9.89(d,J=7.78Hz,1H),8.70(s,1H),7.96-8.09(m,2H),7.80-7.87(m,2H),7.70(br d,J=7.65Hz,1H),7.61(d,J=8.66Hz,1H),7.44(dd,J=9.10,2.82Hz,1H),7.19-7.32(m,4H),5.33(br t,J=7.28Hz,1H),3.86(br d,J=6.65Hz,1H),3.76(t,J=6.65Hz,2H),3.21(br d,J=11.92Hz,1H),2.99(br t,J=9.35Hz,1H),2.84(br d,J=10.79Hz,1H),2.77(brt,J=7.47Hz,2H),2.69(brt,J=6.65Hz,3H),2.56(br s,2H),2.47(s,3H),2.44(br s,1H),2.26-2.37(m,1H),1.51(d,J=6.90Hz,3H),1.36(s,9H),0.99(d,J=6.27Hz,3H)ppm. MS(ESI)m / z 772.2(M+H) + .
[0149] Example 2
[0150] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4- Oxadiazole-5-carboxamide
[0151] Example 2A
[0152] (R)-tert-Butyl 3-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0153] The title compound was prepared according to the procedure used for Example 1K substituting (R)-tert-butyl 3-methylpiperazine-1-carboxylate for (S)-tert-butyl 3-methylpiperazine-1-carboxylate. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 8.13-8.24 (m, 2H), 7.43 (dd, J = 9.32, 3.06 Hz, 1H), 4.32 (br s, 1H), 3.85-4.03 (br s, 1H), 3.79 (brd, J = 12.88 Hz, 2H), 2.97-3.30 (m, 3H), 1.43 (s, 9H), 1.08 (d, J = 6.50 Hz, 3H) ppm. MS (ESI) m / z 323.2 (M+H) + .
[0154] Example 2B
[0155] (R)-tert-Butyl 4-(6-aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate
[0156] The title compound was prepared according to the procedure for Example 1L, substituting Example 2A for Example 1K. 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.62 (d, J = 2.63 Hz, 1H), 7.20 (dd, J = 8.76, 2.75 Hz, 1H), 6.40 (d, J = 8.76 Hz, 1H), 5.54 (s, 2H), 3.56 (br d, J = 10.76 Hz, 1H), 3.40 (br s, 2H) 3.17 (br s, 2H), 2.71-2.88 (m, 2H), 1.41 (s, 9H), 0.76 (d, J = 6.13 Hz, 3H) ppm. MS (ESI) m / z 293.1 (M+H) + .
[0157] Example 2C
[0158] (R)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methyl tert-butyl ester
[0159] The title compound was prepared according to the procedure used for Example 1N, substituting Example 2B for Example 1L. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.99 (s, 1H), 9.87 (d, J = 7.78 Hz, 1H), 8.70 (d, J = 1.00 Hz, 1H), 7.98-8.07 (m, 2H), 7.79-7.88 (m, 2H), 7.71 (brd, J = 9.16 Hz, 1H), 7.60 (d, J = 8.66 Hz, 1H), 7.45 (dd, J = 9.10, 2.82 Hz, 1H), 5.33 (quin, J=7.25Hz,1H),3.75-3.88(m,2H),3.56-3.65(m,1H),3.11-3.22(m,2H),2.90(s,1H),2.52(brs ,1H),2.47(s,3H),1.51(d,J=7.03Hz,3H),1.42(s,9H),1.36(s,9H),0.89(d,J=6.40Hz,3H)ppm. MS(ESI)m / z 656.3(M+H) + .
[0160] Example 2D
[0161] 3-(tert-butyl)-N-((R)-1-(2-methyl-4-(6-((5-((R)-2-methylpiperazin-1-yl)pyridin-2-yl) (amino)pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0162] The title compound was prepared according to the procedure used for Example 10, substituting Example 2C for Example 1N. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.97 (s, 1H), 9.87 (d, J = 7.78 Hz, 1H), 8.70 (d, J = 1.00 Hz, 1H), 8.03 (brs, 1H), 7.98 (d, J = 2.76 Hz, 1H), 7.80-7.87 (m, 2H), 7.69 (brd, J = 8.66 Hz, 1H), 7.60 (d, J = 8.66 Hz, 1H), 7.41 (dd, J = 9.16, 2.89 Hz, 1H), 5.26-5. 40(m,1H),3.65-3.77(m,1H),3.01-3.15(m,1H),2.90-2.98(m,2H),2.84-2.90(m,1H),2.69-2.79(m,2H) ,2.52(brd,J=1.88Hz,1H),2.47(s,3H),1.51(d,J=6.90Hz,3H),1.36(s,9H),0.96(d,J=6.53Hz,3H)ppm. MS(ESI)m / z 556.4(M+H) + .
[0163] Example 2E
[0164] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4- Oxadiazole-5-carboxamide
[0165] The title compound was prepared according to the procedure used for Example 1P, substituting Example 2D for Example 10. 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.31 (brs, 1H), 9.97 (s, 1H), 9.87 (br d,J=6.02Hz,1H),8.70(d,J=0.88Hz,1H),7.94-8.10(m,2H),7.78-7.89(m,2H),7.70(brd,J=8.03Hz,1H),7.60(d,J=8.66Hz,1H),7.43(dd,J=9. 16,2.89Hz,1H),7.18-7.32(m,4H),5.24-5.42(m,1H),3.81-3.90(m,1H ),3.76(t,J=6.65Hz,2H),3.16-3.26(m,1H),2.93-3.05(m,1H),2.84(br d,J=10.67Hz,1H),2.73-2.81(m,2H),2.67-2.73(m,3H),2.53-2.62(m,2H),2.47(s,3H),2.44(br s,1H),2.27-2.36(m,1H),1.51(d,J=7.03Hz,3H),1.36(s,9H),0.99(d,J=6.40Hz,3H)ppm. MS(ESI)m / z 772.2(M+H) + .
[0166] Example 3
[0167] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxylic acid amine
[0168] Example 3A
[0169] tert-Butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0170] The title compound was prepared according to the procedure used for Example 1K, substituting piperazine-1-carboxylic acid tert-butyl ester for (S)-3-methylpiperazine-1-carboxylic acid tert-butyl ester. MS (ESI) m / z 309.2 (M+H) + .
[0171] Example 3B
[0172] tert-Butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate
[0173] The title compound was prepared according to the procedure for Example 1L, substituting Example 3A for Example 1K. MS (ESI) m / z 279.3 (M+H) + .
[0174] Example 3C
[0175] (R)-4-(6-((6-(4-(1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methylbenzene tert-butyl)pyrimidin-4-yl)amino)pyridin-3-yl)piperazine-1-carboxylate
[0176] The title compound was prepared according to the procedure used for Example 1N, substituting Example 3B for Example 1L. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.03 (s, 1H), 9.90 (d, J = 7.8 Hz, 1H), 8.71 (s, 1H), 8.06 (br d, J = 2.9 Hz, 2H), 7.85-7.80 (m, 2H), 7.71 (br d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.47 (dd, J = 2.9, 9.1 Hz, 1H), 5.38-5.28 (m, 1H), 3.46 (br d,J=4.8Hz,4H),3.12-3.02(m,4H),2.47(s,3H),1.51(d,J=6.9Hz,3H),1.42(s,9H),1.37-1.34(m,9H)ppm. MS(ESI)m / z 642.4(M+H) + .
[0177] Example 3D
[0178] (R)-3-(tert-butyl)-N-(1-(2-methyl-4-(6-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidine- 4-(4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0179] The title compound was prepared according to the procedure used for Example 10, substituting Example 3C for Example 1N. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.01 (s, 1H), 9.89 (d, J = 7.8 Hz, 1H), 8.71 (s, 1H), 8.14-7.95 (m, 2H), 7.89-7.77 (m, 2H), 7.71 (br d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.46 (dd, J = 2.9, 9.1 Hz, 1H), 5.33 (quin, J = 7.1 Hz, 1H), 3.19-3.11 (m, 4H), 3.05-2.96 (m, 4H), 2.47 (s, 3H), 1.51 (d, J = 7.0 Hz, 3H), 1.36 (s, 9H) ppm. MS (ESI) m / z 542.3 (M+H) + .
[0180] Example 3E
[0181] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxylic acid amine
[0182] The title compound was prepared according to the procedure used for Example 1P, substituting Example 3D for Example 10. 1 H NMR (500 MHz, dimethyl sulfoxide-d6): δ ppm 10.34 (s, 1H), 9.99 (s, 1H), 9.88 (d, J = 7.8 Hz, 1H), 8.70 (s, 1H), 8.08-8.00 (m, 2H) 7.85-7.80 (m, 2H), 7.69 (brs, 1H), 7.63-7.58 (m, 1H), 7.47 (dd, J = 9.1, 3.0 Hz, 1H), 7.30-7.21 (m, J =8.3Hz,4H),5.33(p,J=7.1Hz,1H),3.76(t,J=6.7Hz,2H),3.14(brs,4H),2.79(brs,2H), 2.70(t,J=6.7Hz,2H),2.61(brs,5H),2.47(s,3H),1.51(d,J=7.0Hz,3H),1.36(s,9H)ppm. MS(ESI)m / z 758.3(M+H) + .
[0183] Example 4
[0184] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazine-1- yl)-3-fluorophenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl 1,2,4-oxadiazole-5-carboxamide
[0185] Example 4A
[0186] (E)-2-(3-Fluoro-4-nitrophenyl)-N,N-dimethylethylene-1-amine
[0187] The mixture of 2-fluoro-4-methyl-1-nitrobenzene (1.50kg, 9.63mol) and N,N-dimethylformamide-dimethyl acetal (1.72kg, 14.5mol, 1.92L) in N,N-dimethylformamide (2.4L) is degassed and purged with nitrogen three times, and the mixture is stirred for 2 hours at 120 ° C (internal reading) under nitrogen. The reaction mixture is concentrated under reduced pressure. The crude material is ground and filtered with petroleum ether / tert-butyl methyl ether (1: 1, 10.0L). The filter cake is washed with petroleum ether / tert-butyl methyl ether (1: 1, 2.0L), and vacuum dried to obtain the title compound. 1 H NMR (400MHz, CDCl3): δppm 7.92 (t, J = 8.4Hz, 1H), 7.03 (d, J = 13.6Hz, 1H), 6.89-6.84 (m, 2H), 5.05 (d, J = 13.2Hz, 1H), 2.95 (s, 6H) ppm.
[0188] Example 4B
[0189] 2-(3-Fluoro-4-nitrophenyl)ethan-1-ol
[0190] Example 4A (1.00 kg, 4.76 mol) was added to aqueous hydrochloric acid (4M, 7.50 L) in small portions at ambient temperature. The mixture was stirred at ambient temperature for 12 hours and extracted with 2-methyltetrahydrofuran (3.0 L × 7). The combined organic phase was washed with brine (5.0 L) and dried over sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to a volume of 10 L and refrigerated in an ice bath. Sodium borohydride (214 g, 5.68 mol) was added to the mixture in small portions in an ice bath, and the reaction mixture was stirred at ambient temperature for 16 hours. The mixture was refrigerated in an ice bath and quenched with 0.5 N aqueous hydrochloric acid (5.0 L). The organic phase was separated, washed with brine (3.0 L), dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the crude title compound.
[0191] Example 4C
[0192] tert-Butyl(3-fluoro-4-nitrophenylethoxy)dimethylsilane
[0193] To the mixture of thick embodiment 4B (660g, 3.56mol) and imidazoles (364g, 5.34mol) in tetrahydrofuran (4.4L) at ambient temperature, tert-butyldimethylsilyl chloride (804g, 5.34mol, 654mL) is added in batches. The mixture is stirred at ambient temperature for 12 hours, quenched by adding water (3.0L), and diluted with ethyl acetate (3.0L). The organic layer is separated, washed with salt water (5.0L), dried over sodium sulfate and filtered. The filtrate is concentrated under reduced pressure. Residue is subjected to silica gel flash column chromatography (petroleum ether and ethyl acetate) to obtain the title compound. 1 H NMR (400MHz, CDCl3): δppm 7.92-8.05(m,1H),7.11-7.20(m,2H),3.79-3.92(m,2H),2.80-2.93(m,2H),0.80(s,9H),-0.09(s,6H)ppm.
[0194] Example 4D
[0195] 4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-fluoroaniline
[0196] To a suspension of Pd / C (2.346 g, 2.204 mmol) in tetrahydrofuran (100 mL) was added Example 4C (5.5 g, 18.37 mmol) at 25°C. The resulting mixture was stirred at 25°C for 12 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure at 40°C to give the title compound. MS (ESI) m / z 270.1 (M+H) + .
[0197] Example 4E
[0198] 3-((4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-fluorophenyl)amino)propanoic acid
[0199] To a solution of Example 4D (2.5 g, 9.28 mmol) in toluene (25 mL) was added acrylic acid (0.802 g, 11.13 mmol). The reaction mixture was heated to 120 °C and stirred for 16 hours. The reaction mixture was cooled to 20 °C and concentrated under reduced pressure to give the crude title compound. MS (ESI) m / z 342.1 (M+H) + .
[0200] Example 4F
[0201] Ethyl 4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-3-fluorophenylacetate
[0202] To a solution of Example 4E (3 g, 8.78 mmol) in acetic acid (30 mL) was added urea (1.583 g, 26.4 mmol). The reaction mixture was heated to 120°C and stirred for 16 hours. The reaction mixture was cooled to 20°C and concentrated under reduced pressure. The residue was purified by preparative HPLC (Phenomenex C18 column, 50*250 mm, 10 μm, using 0.1% formic acid in water and acetonitrile as mobile phase) to purify the crude material to give the title compound. MS (ESI) m / z 295.1 (M+H) + .
[0203] Example 4G
[0204] 1-(2-Fluoro-4-(2-hydroxyethyl)phenyl)dihydropyrimidine-2,4(1H,3H)-dione
[0205] To a solution of Example 4F (1.1 g, 3.74 mmol) in water (1 mL) was added concentrated hydrochloric acid (37%, 1 mL) at 20°C. The reaction mixture was stirred at 20°C for 12 hours. The reaction mixture was concentrated under reduced pressure to give the title compound. MS (ESI) m / z 253.1 (M+H) + .
[0206] Example 4H
[0207] 1-(4-(2-bromoethyl)-2-fluorophenyl)dihydropyrimidine-2,4(1H,3H)-dione
[0208] To a solution of Example 4G (0.3 g, 1.189 mmol) in dichloromethane (20 mL) was added CBr (0.789 g, 2.379 mmol) at 0°C, followed by Ph P (0.624 g, 2.379 mmol). The reaction mixture was stirred at 20°C for 12 hours. The reaction mixture was concentrated under reduced pressure at 40°C. The residue was purified by silica gel flash column chromatography (ethyl acetate in petroleum ether, 0%-100%) to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.47 (s, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.27 (brd, J = 11.2 Hz, 1H), 7.16 (brd, J = 7.6 Hz, 1H), 3.77 (t, J = 7.2 Hz, 2H), 3.70 (t, J = 6.8 Hz, 2H), 3.16 (t, J = 7.2 Hz, 2H), 2.71 (t, J = 6.8 Hz, 2H) ppm. MS (ESI) m / z 315.0, 317.0 (M+H) + .
[0209] Example 4I
[0210] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazine-1- yl)-3-fluorophenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl 1,2,4-oxadiazole-5-carboxamide
[0211] To a solution of Example 10 (80 mg, 0.14 mmol) in N,N-dimethylformamide (1 mL) was added Example 4H (54 mg, 0.17 mmol), sodium iodide (65 mg, 0.43 mmol) and N,N-diisopropylethylamine (56 mg, 0.43 mmol). The mixture was stirred at 80 °C for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was directly subjected to reverse phase preparative HPLC to give the title compound (Gilson GX-281 system, Waters TM Xbridge C18 column, 30×100 mm×10 μm, 10 mM ammonium bicarbonate in water and acetonitrile as mobile phase). 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.46 (s, 1H), 9.99 (s, 1H), 9.89 (d, J = 7.89 Hz, 1H), 8.70 (d, J = 0.66 Hz, 1H), 7.96-8.08 (m, 2H), 7.80-7.86 (m, 2H), 7.66-7.75 (m, 1H), 7.60 (d, J = 8.77 Hz, 1H), 7.44 (dd, J = 9.21, 2.85Hz,1H),7.33(t,J=8.11Hz,1H),7.24(dd,J=11.62,1.53Hz,1H),7.15(dd,J=8.11, 1.53Hz,1H),5.33(t,J=7.34Hz,1H),3.82-3.91(m,1H),3.69(t,J=6.69Hz,2H),3.21(br d,J=11.84Hz,1H),2.98(br t,J=9.32Hz,1H),2.77-2.83(m,2H),2.69-2.72(m,2H),2.53-2.64(m,2H),2.52(d,J=1.75Hz,2H),2.47(s, 3H), 2.41-2.46 (m, 1H), 2.26-2.32 (m, 1H), 1.51 (d, J = 7.02Hz, 3H), 1.36 (s, 9H), 0.98 (d, J = 6.36Hz, 3H) ppm. LC / MS(ESI+)m / z 790.3(M+H) + .
[0212] Example 5
[0213] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-oxadiazine-1- yl)-3-fluorophenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl 1,2,4-oxadiazole-5-carboxamide
[0214] To a solution of Example 2D (100 mg, 0.18 mmol) in N,N-dimethylformamide (2 mL) was added Example 4H (68 mg, 0.22 mmol), sodium iodide (81 mg, 0.54 mmol) and N,N-diisopropylethylamine (70 mg, 0.54 mmol). The mixture was stirred at 80 °C for 16 hours. The mixture was cooled to ambient temperature and filtered. The filtrate was directly subjected to reverse phase preparative HPLC to isolate the title compound (Gilson GX-281 system, Phenomenex C18 column, 30×75 mm×3 μm, 0.1% formic acid in water and acetonitrile as mobile phase). 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.45 (s, 1H), 9.99 (s, 1H), 9.88 (d, J = 7.82 Hz, 1H), 8.70 (s, 1H), 7.98-8.07 (m, 2H), 7.79-7.87 (m, 2H), 7.66-7.74 (m, 1H), 7.60 (d, J = 8.68 Hz, 1H), 7.40-7.48 (m, 1H), 7.33 (t, J = 8.19 Hz, 1H), 7.21-7.28 (m, 1H), 7.15 (d, J = 8.31 Hz, 1H), 5.24-5.44 (m ,1H),3.76-3.97(m,1H),3.69(t,J=6.66Hz,2H),3.13-3.26(m,2H),2.94-3.06(m,1H),2.77-2.92(m,3H),2.71(t,J=6.66H z,3H),2.56-2.65(m,1H),2.47(s,3H),2.33-2.46(m,2H),1.51(d,J=6.85Hz,3H),1.36(s,9H),0.98(d,J=6.24Hz,3H)ppm. LC / MS(ESI + ):m / z 790.2(M+H) + .
[0215] Example 6
[0216] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4- Oxadiazole-5-carboxamide
[0217] Example 6A
[0218] (S)-tert-Butyl 3-ethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0219] 5-Fluoro-2-nitropyridine (1.00 g, 7.04 mmol) and (S)-3-ethylpiperazine-1-carboxylic acid tert-butyl ester (1.96 g, 9.15 mmol) were dissolved in N,N-dimethylformamide, and potassium carbonate (2.92 g, 21.11 mmol) was added. The reaction mixture was stirred at 70 ° C for 15 hours, and concentrated under reduced pressure to remove most of the solvent. The residue was diluted with dichloromethane, washed with water, dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to produce a crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 8.21 (d, J = 2.88 Hz, 1H), 8.15 (d, J = 9.26 Hz, 1H), 7.42 (dd, J = 9.32, 2.94 Hz, 1H), 3.89-4.17 (m, 3H), 3.82 (br d, J = 12.88 Hz, 1H), 2.90-3.27 (m, 3H), 1.47-1.69 (m, 2H), 1.42 (s, 9H), 0.90 (br s, 3H) ppm. LC / MS (ESI + ):m / z 337.0(M+H) + .
[0220] Example 6B
[0221] (S)-4-(6-Aminopyridin-3-yl)-3-ethylpiperazine-1-carboxylic acid tert-butyl ester
[0222] Example 6A (2.0 g, 5.95 mmol) was dissolved in methanol (200 mL). Pd / C (10 wt %, 0.32 g, 3.0 mmol) was added to the mixture. The reaction mixture was hydrogenated at ambient temperature for 2 days using a hydrogen balloon. The mixture was filtered through diatomaceous earth, and the solid cake was washed with methanol and ethyl acetate. The filtrate was concentrated under reduced pressure to obtain the crude title compound. 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.59 (br d, J = 2.01 Hz, 1H), 7.12-7.21 (m, 1H), 6.40 (d, J = 8.78 Hz, 1H), 5.46 (brs, 2H), 3.47-3.76 (m, 2H), 2.98-3.23 (m, 2H), 2.85 (brd, J = 4.64 Hz, 2H), 2.52 (brd, J = 1.88 Hz, 1H), 1.41 (s, 9H), 1.35 (s, 1H), 1.25 (br s, 1H), 0.77 (brt, J = 7.22 Hz, 3H) ppm. LC / MS (ESI + ):m / z 307.2(M+H) + .
[0223] Example 6C
[0224] (S)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methyl tert-butyl ester
[0225] To a solution of Example 1E (300 mg, 0.75 mmol) in 1,4-dioxane (6 mL) was added Example 6B (253 mg, 0.83 mmol), Pd2(dba)3 (CAS 52409-22-0, 34 mg, 0.038 mmol), XantPhos (CAS161265-03-8, 43 mg, 0.075 mmol) and cesium carbonate (489 mg, 1.50 mmol). The mixture was degassed using an argon stream and stirred at 100 ° C for 16 hours. The reaction mixture was cooled, diluted with ethyl acetate, and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography using ethyl acetate and petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.98 (s, 1H), 9.89 (d, J = 7.78 Hz, 1H), 8.70 (s, 1H), 7.96-8.07 (m, 2H), 7.80-7.86 (m, 2H), 7.66-7.74 (m, 1H), 7.60 (d, J = 8.66 Hz, 1H), 7.38-7.48 (m, 1H), 5.33 (quin, J = 7.09 Hz, 1H), 3.90 (br d, J = 11.04 Hz, 2H), 3.60 (br dd,J=6.53,3.01Hz,1H),3.12-3.29(m,2H),2.89-3.05(m,2H),2.47(s,3H),1.61(s,1H),1.51(br d,J=6.90Hz,3H),1.42(s,9H),1.36(s,9H),1.21-1.31(m,1H),0.86(br s,3H)ppm. LC / MS(ESI+):m / z670.4(M+H) + .
[0226] Example 6D
[0227] 3-(tert-butyl)-N-((R)-1-(4-(6-((5-((S)-2-ethylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine (4-pyridin-1-yl)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0228] To a solution of Example 6C (150 mg, 0.22 mmol) in 1,4-dioxane (3 mL) was added hydrochloric acid (4 N in dioxane, 3 mL) dropwise at ambient temperature. The mixture was stirred for 2 hours, concentrated under reduced pressure, diluted with water (5 mL), and treated with a saturated aqueous sodium carbonate solution to adjust the pH to 8. The mixture was extracted with ethyl acetate (15 mL, three times), and the organic phase was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give the crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.94 (s, 1H), 9.89 (d, J = 7.78 Hz, 1H), 8.69 (s, 1H), 7.92-8.05 (m, 2H), 7.80-7.87 (m, 2H), 7.63-7.72 (m, 1H), 7.60 (d, J = 8.66 Hz, 1H), 7.37 (dd, J = 9.03, 2.89 Hz, 1H), 5.33 (quin, J = 7.09 Hz, 1H), 3.45 (br dd,J=6.71,2.45Hz,1H),3.09-3.17(m,1H),2.80-2.94(m,4H),2.66-2.74(m,1H),2.47(s,3H),1.75(ddd,J= 13.61,9.47,7.40Hz,1H),1.51(d,J=6.90Hz,3H),1.36(s,9H),1.22-1.30(m,1H),0.79(t,J=7.47Hz,3H)ppm. LC / MS(ESI+):m / z 570.4(M+H) + .
[0229] Example 6E
[0230] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4- Oxadiazole-5-carboxamide
[0231] Example 6D (480 mg, 0.79 mmol), Example 1J (327 mg, 0.95 mmol), N,N-diisopropylethylamine (277 μL, 1.58 mmol) and potassium iodide (657 mg, 3.96 mmol) were mixed in N,N-dimethylformamide (8 mL). The mixture was stirred at 80 °C for 4 hours. The mixture was cooled, quenched with a few drops of formic acid, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex AXA C18 column, 30×250 mm×5 μm, 0.1% formic acid in water and acetonitrile as mobile phase). 1H NMR (500 MHz, dimethyl sulfoxide-d6): δ ppm 9.89 (s, 1H), 9.53 (s, 1H), 9.38 (d, J = 7.6 Hz, 1H), 8.64 (d, J = 1.1 Hz, 1H), 7.94 (dd, J = 11.8, 2.1 Hz, 2H), 7.84–7.78 (m, 2H), 7.64 (d, J = 9.0 Hz, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.33 (dd, J = 9.1, 3.1 Hz, 1H), 7.28–7.18 (m, 4H), 5.34 (p, J = 7.1 Hz, 1H), 3.73 (t, J = 6. 7Hz,2H),3.53(s,1H),3.24(d,J=12.2Hz,1H),3.10–3.02(m,1H),2.79(ddt,J=14.1,7.8,3.6Hz,4H),2.68(t,J=6.7Hz,2H),2 .60(s,2H),2.45(s,3H),2.41–2.27(m,3H),1.73–1.59(m,1H),1.52(d,J=7.0Hz,3H),1.35(s,9H),0.79(t,J=7.4Hz,3H)ppm. LC / MS(ESI+):m / z 786.7(M+H) + .
[0232] Example 7
[0233] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazine-1- yl)-3-fluorophenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl 1,2,4-oxadiazole-5-carboxamide
[0234] Example 6D (120 mg, 0.21 mmol), Example 4H (100 mg, 0.32 mmol), N,N-diisopropylethylamine (184 μL, 1.05 mmol) and sodium iodide (95 mg, 0.63 mmol) were mixed in acetonitrile (2.4 mL). The mixture was stirred at 80 °C for 16 hours. The mixture was cooled, quenched with a few drops of formic acid, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex C18 column, 30×75 mm×3 μm, 0.1% formic acid in water and acetonitrile as mobile phase). 1HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.46(s,1H),9.96(s,1H),9.89(d,J=7.75Hz,1H),8.69(s,1H),7.94-8.0 5(m,2H),7.80-7.86(m,2H),7.64-7.73(m,1H),7.60(d,J=8.63Hz,1H),7. 37-7.44(m,1H),7.33(t,J=8.19Hz,1H),7.21-7.28(m,1H),7.08-7.17(m, 1H),5.25-5.41(m,1H),3.68(t,J=6.63Hz,2H),3.57-3.65(m,1H),3.00(br t,J=10.57Hz,1H),2.86-2.95(m,2H),2.81(br d,J=6.38Hz,2H),2.71(br t,J=6.63Hz,2H),2.60-2.65(m,1H),2.47(br s,5H),2.21-2.31(m,2H),1.62-1.76(m,1H),1.51(d,J=7.00Hz,3H),1.36(s,9H),1.22-1.31(m,1H),0.81(brt,J=7.38Hz,3H)ppm. LC / MS(ESI+):m / z 804.3(M+H) + .
[0235] Example 8
[0236] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4- Oxadiazole-5-carboxamide
[0237] Example 8A
[0238] (R)-tert-Butyl 3-ethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0239] The title compound was prepared according to the procedure used for Example 6A, substituting (R)-tert-butyl 3-ethylpiperazine-1-carboxylate for (S)-tert-butyl 3-ethylpiperazine-1-carboxylate. LC / MS (ESI + ):m / z 337.0(M+H) + .
[0240] Example 8B
[0241] (R)-tert-Butyl 4-(6-aminopyridin-3-yl)-3-ethylpiperazine-1-carboxylate
[0242] The title compound was prepared according to the procedure used for Example 6B, substituting Example 8A for Example 6A. LC / MS (ESI+ ):m / z 307.2(M+H) + .
[0243] Example 8C
[0244] (R)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methyl tert-butyl ester
[0245] The title compound was prepared according to the procedure for Example 6C, substituting Example 8B for Example 6B. LC / MS (ESI+): m / z 670.1 (M+H) + .
[0246] Example 8D
[0247] 3-(tert-butyl)-N-((R)-1-(4-(6-((5-((R)-2-ethylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine (4-pyridin-1-yl)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0248] The title compound was prepared according to the procedure for Example 6D, substituting Example 8C for Example 6C. LC / MS (ESI+): m / z 570.7 (M+H) + .
[0249] Example 8E
[0250] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4- Oxadiazole-5-carboxamide
[0251] The title compound was prepared according to the procedure for Example 6E, substituting Example 8D for Example 6D. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ9.95 (s, 1H), 9.79 (s, 1H), 9.40 (d, J = 7.5 Hz, 1H), 8.70 (s, 1H), 8.09 (s, 1H), 7.99 (s, 1H), 7.82 (d, J = 7.8 Hz, 2H), 7.74 (d, J = 8.7 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.51 (s, 1H), 7.33-7.28 (m, 4H), 5.34 (p, J=7.1Hz,1H),3.75(t,J=6.7Hz,2H),3.40-3.32(m,4H),3.28(s,2H),3.20(s,1H),3.10-3.03(m,1H),3.00-2.90 (m,3H),2.69(t,J=6.7Hz,2H),2.46-2.45(m,5H),1.52(d,J=6.9Hz,3H),1.35(s,9H),0.83(t,J=7.1Hz,3H)ppm. LC / MS(ESI+):m / z 786.9(M+H) + .
[0252] Example 9
[0253] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}-2,2-dimethylpiperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole 5-Diazolecarboxamide
[0254] Example 9A
[0255] tert-Butyl 3,3-dimethyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0256] 5-Bromo-2-nitropyridine (5.68 g, 28.0 mmol) and tert-butyl 3,3-dimethylpiperazine-1-carboxylate (3.0 g, 14.00 mmol) were dissolved in dioxane (150 mL). Cesium carbonate (9.12 g, 28.0 mmol), BINAP ((R / S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 0.872 g, 1.40 mmol) and tris(dibenzylideneacetone)dipalladium(0) (1.282 g, 1.40 mmol) were added to the mixture. The reaction mixture was stirred at 120 °C for 15 hours under a nitrogen atmosphere. The mixture was cooled and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified using silica gel chromatography (ethyl acetate and hexane) to obtain the title compound. LC / MS (ESI+) m / z 336.9 (M+H) + .
[0257] Example 9B
[0258] tert-Butyl 4-(6-aminopyridin-3-yl)-3,3-dimethylpiperazine-1-carboxylate
[0259] Example 9A (1.1 g, 3.27 mmol) was dissolved in methanol (100 mL). Pd / C (10 wt%, 0.17 g, 1.64 mmol) was added to the mixture. The reaction mixture was hydrogenated using a hydrogen balloon at ambient temperature for 2 days. The mixture was filtered through celite, and the filter cake was washed with methanol and ethyl acetate. The filtrate was concentrated under reduced pressure to give the crude title compound. LC / MS (ESI+) m / z 307.2 (M+H) + .
[0260] Example 9C
[0261] (R)-4-(6-((6-(4-(1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methylbenzene tert-butyl ester
[0262] A stirred mixture of Example 9B (400 mg, 1.30 mmol), Example 1E (522 mg, 1.30 mmol), racemic BINAP-Pd-G3 (CAS 2151915-22-7, 130 mg, 0.13 mmol) and cesium carbonate (1276 mg, 3.92 mmol) in 1,4-dioxane (6.5 mL) was heated in a Biotage TM Initiator + microwave synthesizer at 105 ° C for 2 hours. The mixture was cooled and filtered. The filtrate was concentrated under reduced pressure and purified using silica gel chromatography with ethyl acetate and hexanes to give the title compound. LC / MS (ESI+): m / z 670.6 (M+H) + .
[0263] Example 9D
[0264] (R)-3-(tert-butyl)-N-(1-(4-(6-((5-(2,2-dimethylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidine (4-pyridin-1-yl)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0265] Example 9C (845 mg, 1.26 mmol) was dissolved in 1,4-dioxane (3 mL), and hydrochloric acid (4N in 1,4-dioxane, 1.6 mL) was added to the mixture. The mixture was stirred at ambient temperature for 2 hours and concentrated under reduced pressure to give the crude title compound as a hydrochloride salt. LC / MS (ESI+): m / z 570.7 (M+H) + .
[0266] Example 9E
[0267] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}-2,2-dimethylpiperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole 5-Diazolecarboxamide
[0268] Example 9D (200 mg, 0.35 mmol), Example 1J (145 mg, 0.42 mmol), N,N-diisopropylethylamine (123 μL, 0.70 mmol) and potassium iodide (291 mg, 1.76 mmol) were mixed in N,N-dimethylformamide (3.5 mL). The mixture was stirred at 80 °C for 4 hours. The mixture was cooled, quenched with a few drops of formic acid, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex AXA C18 column, 30×250 mm×5 μm, 0.1% formic acid in water and acetonitrile as mobile phase). 1 H NMR (500 MHz, dimethyl sulfoxide-d6): δ ppm 10.25 (s, 1H), 10.07 (s, 1H), 9.81 (d, J = 7.8 Hz, 1H), 8.68 (d, J = 1.1 Hz, 1H), 8.04 (d, J = 3.0 Hz, 2H), 7.80-7.76 (m, 2H), 7.67 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.50 (dd, J = 8.9, 2.7 Hz, 1H), 7.21 (d, J = 8.6 Hz, 2H), 7.17 (d, J = 8. =8.5Hz,2H),5.27(p,J=7.1Hz,1H),3.70(t,J=6.7Hz,2H),3.01(s,2H),2.70(t,J=7.6Hz,2H),2.64(td,J=6.7, 2.6Hz,2H),2.50–2.43(m,4H),2.41(s,3H),2.37-2.27(m,2H),1.45(d,J=7.0Hz,3H),1.29(s,9H),0.94(s,6H). LC / MS(ESI+)m / z 786.9(M+H) + .
[0269] Example 10
[0270] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-3-fluoro-2-methylphenyl}ethyl]-1, 2,4-Oxadiazole-5-carboxamide
[0271] Example 10A
[0272] 1-Bromo-2-fluoro-4-iodo-3-methylbenzene
[0273] 5L reactor is loaded into 1-bromo-2-fluoro-4-iodobenzene (288g, 0.96mol) in anhydrous tetrahydrofuran (2.0L). The mixture is refrigerated to -60°C, lithium diisopropylamide (2M in tetrahydrofuran, 526mL, 1.05mol) is added, and the mixture is stirred at -60°C for 1 hour. Iodomethane (163g, 1.15mol) is added, and the mixture is stirred at -60°C for 12 hours. The reaction mixture is diluted with water (1.0L) and extracted with methyl tert-butyl ether (1.0L×3). The same reaction is repeated three times on the same scale. The organic layer of four batches combined is washed with brine, dried over sodium sulfate, and filtered. The filtrate is concentrated under reduced pressure to obtain a thick title compound. 1 H NMR (400MHz, CDCl3): δppm 7.46 (d, J = 8.4Hz, 1H), 7.10 (t, J = 7.6Hz, 1H), 2.41 (s, 3H) ppm.
[0274] Example 10B
[0275] 4-Bromo-3-fluoro-2-methylbenzaldehyde
[0276] Example 10A (360g, 1.14mol) and anhydrous tetrahydrofuran (1.8L) were loaded into a 5L reactor and refrigerated to -60°C. iPrMgCl (isopropylmagnesium chloride, 2M in tetrahydrofuran, 572mL, 1.14mol) was added, and the mixture was stirred at -60°C for 1 hour. Morpholine-4-carboxaldehyde (158g, 1.37mol) was added to the mixture at -60°C. The mixture was stirred at 0°C-5°C for 4 hours. The reaction mixture was diluted with saturated aqueous NH4Cl solution (0.8L) and extracted with methyl tert-butyl ether (1.7L×3). The same reaction was repeated twice on the same scale. The organic layer of the three batches combined was washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude title compound. 1 H NMR (400MHz, CDCl3): δppm 10.18 (s, 1H), 7.54 (d, J = 8.4Hz, 1H), 7.45 (d, J = 8.4Hz, 1H), 2.60 (s, 3H) ppm.
[0277] Example 10C
[0278] (S,E)-N-(4-Bromo-3-fluoro-2-methylbenzylidene)-2-methylpropane-2-sulfenamide
[0279] Into a 3L reactor, triisopropyl borate (840 g, 4.47 mol) and crude Example 10B (746 g, 3.44 mol) and (S)-2-methylpropane-2-sulfinamide (542 g, 4.47 mol) were loaded at ambient temperature. The mixture was stirred at 70°C for 12 hours. The mixture was cooled to ambient temperature, diluted with water (3.0 L), extracted with dichloromethane (2.0 L x 2), washed with brine, dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the residue was ground with methyl tert-butyl ether to obtain the title compound. 1 HNMR (400MHz, CDCl3): δppm 8.78 (s, 1H), 7.60 (d, J = 8.4Hz, 1H), 7.49 (t, J = 7.6Hz, 1H), 2.55 (s, 3H), 1.28 (s, 9H) ppm. MS(ESI)m / z 320.0,322.0(M+H) + .
[0280] Example 10D
[0281] (S)-N-((R)-1-(4-bromo-3-fluoro-2-methylphenyl)ethyl)-2-methylpropane-2-sulfenamide
[0282] Anhydrous dichloromethane (4.4L) and Example 10C (220g, 0.69mol) were loaded into a 10L reactor. The mixture was refrigerated to 0°C. CH3MgBr (3.0M in tetrahydrofuran, 573mL, 1.72mol) was added dropwise at 0°C. The mixture was then stirred at ambient temperature for 12 hours. The reaction mixture was refrigerated in an ice bath, and saturated aqueous NH4Cl solution (2.2L) was added to the mixture. The organic phase was separated, and the aqueous phase was extracted with dichloromethane (2.2L×2). The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was ground in hexane, filtered, and dried under reduced pressure to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide): δ ppm 7.52 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 5.43 (d, J = 5.6 Hz, 1H), 4.59 (m, 1H), 2.26 (s, 3H), 1.42 (d, J = 6.8 Hz, 3H), 1.09 (s, 9H) ppm. MS (ESI) m / z 336.0, 338.0 (M+H) + .
[0283] Example 10E
[0284] (S)-N-((R)-1-(3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- (2-Methyl)phenyl)ethyl)-2-methylpropane-2-sulfenamide
[0285] To a solution of Example 10D (10.5 g, 30.0 mmol) in 1,4-dioxane (200 mL) at 20 ° C, bis(pinacolato)diboron (9.13 g, 36.0 mmol) and potassium acetate (5.88 g, 60.0 mmol) were added. The reactor was evacuated and backfilled with nitrogen three times, and then 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (2.45 g, 3.00 mmol) was added. The reaction vessel was evacuated and backfilled with nitrogen three times again. The reaction mixture was heated to 100 ° C and stirred for 16 hours. The reaction mixture was cooled and filtered through a diatomaceous earth pad. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, by eluting with petroleum ether and ethyl acetate to obtain the title compound. 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.38-7.48 (m, 1H), 7.24 (d, J = 7.75 Hz, 1H), 5.35-5.43 (m, 1H), 4.53-4.69 (m, 1H), 2.19 (d, J = 2.00 Hz, 3H), 1.42 (d, J = 6.63 Hz, 3H), 1.28 (s, 12H), 1.08 (s, 9H) ppm.
[0286] Example 10F
[0287] (R)-1-(3-Fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) Ethyl-1-amine
[0288] To a solution of Example 10E (20.0 g, 52.2 mmol) in methyl tert-butyl ether (400 mL) was added hydrochloric acid (4N in methyl tert-butyl ether, 400 mL) dropwise at ambient temperature. The mixture was stirred for 3 hours, concentrated under reduced pressure, and ground in methyl tert-butyl ether (50 mL). The solid was separated by filtration and dried in vacuo to give the crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ 8.63 (br s, 3H), 7.56-7.49 (m, 1H), 7.43 (d, J = 7.9 Hz, 1H), 4.57 (q, J = 6.7 Hz, 1H), 2.22 (d, J = 1.8 Hz, 3H), 1.46 (d, J = 6.6 Hz, 3H), 1.29 (s, 12H) ppm. MS (ESI) m / z 280.0 (M+H) + .
[0289] Example 10G
[0290] (R)-3-(tert-butyl)-N-(1-(3-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (2-(4-(2-((4-((2-( ...
[0291] Triethylamine (23.5 mL, 169 mmol) was added to a solution of Example 10F (7.00 g, 21.1 mmol) and 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid methyl ester (9.70 g, 52.7 mmol) in ethanol (140 mL) at 20°C. The mixture was stirred at 60°C for 12 hours and then concentrated under reduced pressure to remove ethanol. The crude material was purified by silica gel column chromatography, eluted with petroleum ether and ethyl acetate to obtain the title compound. 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.90 (brd, J = 7.6 Hz, 1H), 7.47 (t, J = 6.9 Hz, 1H), 7.38-7.22 (m, 1H), 5.28 (brt, J = 7.2 Hz, 1H), 2.33-2.18 (m, 3H), 1.46 (br d, J = 6.9 Hz, 3H), 1.42-1.19 (m, 21H) ppm. MS (ESI) m / z 432.2 (M+H) + .
[0292] Example 10H
[0293] (R)-3-(tert-butyl)-N-(1-(4-(6-chloropyrimidin-4-yl)-3-fluoro-2-methylphenyl)ethyl)-1,2,4-oxadiazole 5-Diazolecarboxamide
[0294] To a mixture of Example 10G (2.80g, 6.49mmol) and 4,6-dichloropyrimidine (1.93g, 12.98mmol) in tetrahydrofuran (120mL) at 20°C, a solution of potassium phosphate (2.76g, 12.98mmol) in water (30mL) was added. The mixture was degassed using a nitrogen stream at ambient temperature, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (265mg, 0.33mmol) was added to the mixture under N2. The reaction mixture was heated to 80°C and stirred for 2 hours. The mixture was cooled, poured into water and extracted three times with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluted with tetrahydrofuran in petroleum ether to obtain the crude title compound. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.93 (d, J = 7.8 Hz, 1H), 9.07 (s, 1H), 8.30 (s, 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 5.33 (quin, J = 7.2 Hz, 1H), 2.48-2.47 (m, 1H), 2.47 (s, 2H), 1.50 (d, J = 7.0 Hz, 3H), 1.36 (s, 9H) ppm. MS (ESI) m / z 418.2 (M+H) + .
[0295] Example 10I
[0296] (S)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-2- tert-butyl 3-(4-fluoro-3-methylphenyl)pyrimidin-4-yl)amino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate
[0297] To a solution of Example 10H (500 mg, 1.20 mmol) in 1,4-dioxane (10 mL) was added Example 1L (385 mg, 1.32 mmol), Pd2(dba)3 (CAS 52409-22-0, 55 mg, 0.06 mmol), XantPhos (CAS161265-03-8, 69 mg, 0.12 mmol) and cesium carbonate (780 mg, 2.39 mmol). The mixture was degassed using a stream of nitrogen and stirred at 100 °C for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled, diluted with ethyl acetate, filtered through celite, concentrated under reduced pressure and purified by silica gel chromatography using ethyl acetate and petroleum ether to give the title compound. LC / MS (ESI+): m / z 674.4 (M+H) + .
[0298] Example 10J
[0299] 3-(tert-butyl)-N-((R)-1-(3-fluoro-2-methyl-4-(6-((5-((S)-2-methylpiperazin-1-yl)pyridine- 2-yl)amino)pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0300] To a solution of Example 10I (150 mg, 0.223 mmol) in methyl tert-butyl ether (2 mL) was added hydrochloric acid (4N in methyl tert-butyl ether, 2 mL) dropwise. The reaction mixture was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to give the title compound as the hydrochloride salt. LC / MS (ESI+): m / z 574.4 (M+H) + .
[0301] Example 10K
[0302] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-3-fluoro-2-methylphenyl}ethyl]-1, 2,4-Oxadiazole-5-carboxamide
[0303] To a solution of Example 10J (100 mg, 0.17 mmol) in N,N-dimethylformamide (2 mL) was added Example 1J (54 mg, 0.17 mmol), potassium iodide (145 mg, 0.87 mmol) and potassium carbonate (48 mg, 0.35 mmol). The mixture was stirred at 80 °C for 2 hours. The mixture was cooled to ambient temperature, filtered, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Gilson GX-281 system, Phenomenex NX C18 column, 30×75 mm×3 μm, 10 mM ammonium bicarbonate in water and acetonitrile as mobile phase). 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.33 (s, 1H), 10.08 (s, 1H), 9.93 (br d, J = 7.5 Hz, 1H), 8.72 (s, 1H), 7.96 (br d, J = 2.4 Hz, 2H), 7.81 (t, J = 8.0 Hz, 1H), 7.72 (br d, J = 2.0 Hz, 1H), 7.43 (br d,J=8.3Hz,2H),7.32-7.17(m,4H),5.33(quin,J=6.9Hz,1H),3.92-3.83(m,1 H),3.76(t,J=6.7Hz,2H),3.26-3.16(m,1H),2.98(brt,J=9.5Hz,1H),2.85(br d,J=10.6Hz,1H),2.81-2.74(m,2H),2.69(br t,J=6.7Hz,3H),2.61-2.54(m,2H),2.46-2.42(m,1H),2.35(d,J=1.8Hz,3H),2 .31-2.25(m,1H),1.52(d,J=7.0Hz,3H),1.36(s,9H),0.98(d,J=6.3Hz,3H)ppm. MS(ESI)m / z 790.3(M+H) + .
[0304] Embodiment 11
[0305] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-3-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole- 5-Formamide
[0306] Example 11A
[0307] (R)-4-(6-((6-(4-(1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-2-fluoro-3- tert-butyl ester (methylphenyl)pyrimidin-4-yl)amino)pyridin-3-yl)piperazine-1-carboxylate
[0308] To a solution of Example 10H (2.40 g, 5.46 mmol) in 1,4-dioxane (80 mL) was added Example 3B (1.67 g, 6.00 mmol), Pd2(dba)3 (CAS 52409-22-0, 250 mg, 0.27 mmol), XantPhos (CAS161265-03-8, 316 mg, 0.32 mmol) and cesium carbonate (3.56 g, 10.91 mmol). The mixture was degassed using a stream of nitrogen and stirred at 100 °C for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled, diluted with ethyl acetate, filtered through diatomaceous earth, concentrated under reduced pressure and purified by silica gel chromatography using ethyl acetate and petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.15 (s, 1H), 9.96 (d, J = 7.8 Hz, 1H), 8.75 (s, 1H), 8.08-7.94 (m, 2H), 7.87-7.68 (m, 2H), 7.52-7.40 (m, 2H), 5.41-5.29 (m, 1H), 3.48 (br d, J = 4.8 Hz, 4H), 3.14-3.03 (m, 4H), 2.37 (d, J = 1.9 Hz, 3H), 1.53 (d, J = 7.0 Hz, 3H), 1.43 (s, 9H), 1.38 (s, 9H) ppm. LC / MS (ESI+): m / z 660.4 (M+H) + .
[0309] Example 11B
[0310] (R)-3-(tert-butyl)-N-(1-(3-fluoro-2-methyl-4-(6-((5-(piperazin-1-yl)pyridin-2-yl)amino) Pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0311] To a solution of Example 11A (3.15 g, 4.30 mmol) in 1,4-dioxane (40 mL) was added hydrochloric acid (4 N in 1,4-dioxane, 40 mL) dropwise. The reaction mixture was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to give the title compound as the hydrochloride salt. 1HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.11 (s, 1H), 10.06-9.88 (m, 1H), 8.74 (s, 1H), 8.00 (br s, 2H), 7.87-7.64 (m, 2H), 7.45 (br d, J = 7.1 Hz, 2H), 5.35 (br t, J = 6.9 Hz, 1H), 3.04 (br s, 4H), 2.86 (br s, 4H), 2.37 (br s, 3H), 1.53 (brd, J = 6.6 Hz, 3H), 1.37 (s, 9H) ppm. LC / MS (ESI+): m / z 560.3 (M+H) + .
[0312] Example 11C
[0313] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-3-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole- 5-Formamide
[0314] To a solution of Example 11B (130 mg, 0.21 mmol) in N,N-dimethylformamide (1 mL) was added Example 1J (86 mg, 0.25 mmol), sodium bromide (129 mg, 1.25 mmol) and sodium bicarbonate (70 mg, 0.84 mmol). The mixture was stirred at 80 °C for about 12 hours. The mixture was cooled to ambient temperature, filtered, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex NX C18 column, 40×80 mm×3 μm, 10 mM ammonium bicarbonate in water and acetonitrile as mobile phase). 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.34 (s, 1H), 10.09 (s, 1H), 9.94 (br d, J = 7.63 Hz, 1H), 8.72 (s, 1H), 8.01 (br s, 1H), 7.81 (br t, J = 8.07 Hz, 1H), 7.39-7.49 (m, 2H), 7.21-7.30 (m, 3H), 5.33 (br t, J = 6.94 Hz, 1H), 3.76 (t, J = 6.63 Hz, 2H), 3.14 (br s,5H),2.74-2.82(m,2H),2.69(brt,J=6.69Hz,2H),2.52-2.64(m,6H),2.35(d,J=1.50Hz,3H),1.51(brd,J=6.88Hz,3H),1.36(s,9H)ppm. MS(ESI)m / z 776.3(M+H) + .
[0315] Example 12
[0316] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-5-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole- 5-Formamide
[0317] Example 12A
[0318] 4-Bromo-5-fluoro-2-methylbenzaldehyde
[0319] 1- bromo-2- fluoro-4- iodo-5- methylbenzene (25g, 79mmol) and anhydrous tetrahydrofuran (400mL) are loaded into a 2L flask and refrigerated to -25°C. iPrMgCl (isopropylmagnesium chloride, 1.3M in tetrahydrofuran, 67.2mL, 87mmol) is added, and the mixture is stirred at -25°C for 30 minutes. Anhydrous N, N- dimethylformamide (7.38mL, 96mmol) is added to the mixture at -25°C. The mixture is warmed to 0°C to 5°C and stirred for 1.5 hours. The reaction mixture is carefully quenched with 1N hydrochloric acid (200mL), and the mixture is extracted with ethyl acetate (three times). The combined organic phase is dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude title compound. 1 HNMR (400MHz, CDCl3): δppm 10.21 (d, J=1.7Hz, 1H), 7.58-7.54 (m, 2H), 2.64 (s, 3H)ppm.
[0320] Example 12B
[0321] (S,E)-N-(4-Bromo-5-fluoro-2-methylbenzylidene)-2-methylpropane-2-sulfenamide
[0322] Into 1L flask, load Example 12A (17.00g, 78.0mmol) and dichloromethane (340mL).Into the stirred solution, add (S)-2-methylpropane-2-sulfinamide (10.44g, 86.0mmol) and ethoxide titanium (IV) (35.7g, 157mmol) at ambient temperature.The mixture is stirred for 16 hours, and then quenched with water (36mL) at 0°C.Filter the mixture, and the filter cake is washed with dichloromethane (using 300mL three times).The filtrate is concentrated under reduced pressure, and the crude material is ground in hexane (50mL) for 30 minutes.Solid is separated by filtration, washed with hexane, and dried under high vacuum to obtain the title compound.
[0323] Example 12C
[0324] (S)-N-((R)-1-(4-bromo-5-fluoro-2-methylphenyl)ethyl)-2-methylpropane-2-sulfenamide
[0325] A 2L flask was charged with anhydrous dichloromethane (400 mL) and Example 12B (21.6 g, 67.5 mmol). The mixture was refrigerated to 0°C. CH3MgBr (3.0 M in tetrahydrofuran, 56.2 mL, 169 mol) was added dropwise at 0°C. The mixture was then stirred at 0°C for 5 hours. The reaction mixture was quenched with saturated aqueous NH4Cl solution (500 mL). The organic phase was separated, and the aqueous phase was extracted with dichloromethane (100 mL×3). The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using ethyl acetate and petroleum ether to isolate the title compound. MS (ESI) m / z 335.9, 337.9 (M+H) + .
[0326] Example 12D
[0327] (S)-N-((R)-1-(5-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- (2-Methyl)phenyl)ethyl)-2-methylpropane-2-sulfenamide
[0328] To a solution of Example 12C (15.0 g, 43.3 mmol) in 1,4-dioxane (300 mL) at 20 ° C, bis(pinacolato)diboron (13.19 g, 51.9 mmol) and potassium acetate (8.49 g, 87.0 mmol) were added. The reactor was evacuated and backfilled with nitrogen three times, and then 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (3.53 g, 4.33 mmol) was added. The reaction vessel was evacuated and backfilled with nitrogen three times again. The reaction mixture was heated to 100 ° C and stirred for 16 hours. The reaction mixture was cooled and filtered through a diatomaceous earth pad. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, by eluting with petroleum ether and ethyl acetate to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.51 (d, J = 6.0 Hz, 1H), 7.05 (d, J = 10.5 Hz, 1H), 4.80 (br d, J = 3.4 Hz, 1H), 3.49 (br d, J = 2.6 Hz, 1H), 2.34 (s, 3H), 1.50-1.44 (m, 3H), 1.36 (s, 12H), 1.23-1.19 (m, 9H) ppm.
[0329] Example 12E
[0330] (R)-1-(5-Fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) Ethyl-1-amine
[0331] To a solution of Example 12D (3.00 g, 7.83 mmol) in dichloromethane (10 mL) was added hydrochloric acid (4N in 1,4-dioxane, 30 mL) dropwise at ambient temperature. The mixture was stirred for 24 hours and concentrated under reduced pressure to give the crude title compound. MS (ESI) m / z 280.0 (M+H) + .
[0332] Example 12F
[0333] (R)-3-(tert-butyl)-N-(1-(5-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (2-(4-(2-((4-((2-( ...
[0334] To a solution of Example 12E (3.80 g, 13.61 mmol) and methyl 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylate (3.76 g, 20.42 mmol) in tetrahydrofuran (60 mL) was added 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (6.16 mL, 40.80 mmol) at ambient temperature. The reaction mixture was stirred at 85 °C for 16 hours, cooled, concentrated under reduced pressure, and purified by silica gel column chromatography and eluted with hexanes and ethyl acetate to give the title compound. MS (ESI) m / z 432.2 (M+H) + .
[0335] Example 12G
[0336] (R)-3-(tert-butyl)-N-(1-(4-(6-chloropyrimidin-4-yl)-5-fluoro-2-methylphenyl)ethyl)-1,2,4-oxadiazole 5-Diazolecarboxamide
[0337] The title compound was prepared according to the procedure for Example 10H, substituting Example 12F for Example 10G. MS (ESI) m / z 418.2 (M+H) + .
[0338] Example 12H
[0339] (R)-4-(6-((6-(4-(1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-2-fluoro-5- tert-butyl ester (methylphenyl)pyrimidin-4-yl)amino)pyridin-3-yl)piperazine-1-carboxylate
[0340] A stirred mixture of Example 3B (406 mg, 1.46 mmol), Example 12G (435 mg, 1.04 mmol), racemic BINAP-Pd-G3 (CAS 2151915-22-7, 99 mg, 0.1 mmol) and cesium carbonate (746 mg, 2.29 mmol) in 1,4-dioxane (6.5 mL) was heated at 110° C. for 4 hours under a nitrogen atmosphere. The mixture was cooled, filtered, concentrated under reduced pressure, and the residue was purified using silica gel chromatography with ethyl acetate and hexanes to isolate the title compound. LC / MS (ESI+): m / z 660.4 (M+H) + .
[0341] Example 12I
[0342] (R)-3-(tert-butyl)-N-(1-(5-fluoro-2-methyl-4-(6-((5-(piperazin-1-yl)pyridin-2-yl)amino) Pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0343] The title compound was prepared according to the procedure used for Example 11B, substituting Example 12H for Example 11A. MS (ESI) m / z 560.4 (M+H) + .
[0344] Example 12J
[0345] 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl] ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-5-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole- 5-Formamide
[0346] To a solution of Example 12I (100 mg, 0.17 mmol) in N,N-dimethylformamide (1.7 mL) was added Example 1J (81 mg, 0.24 mmol), potassium iodide (139 mg, 0.84 mmol) and N,N-diisopropylethylamine (205 μL, 1.17 mmol). The mixture was stirred at 80 °C for 2 hours. The mixture was cooled to ambient temperature, filtered, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex AXAC18 column, 30×250 mm×5 μm, 0.1% formic acid in water and acetonitrile as mobile phase). 1H NMR (500 MHz, dimethyl sulfoxide-d6): δ ppm 10.34 (s, 1H), 10.11 (s, 1H), 9.87 (d, J = 7.9 Hz, 1H), 8.73 (s, 1H), 8.04-7.95 (m, 2H) 7.83 (d, J = 8.0 Hz, 1H), 7.72 (brs, 1H), 7.50-7.45 (m, 1H), 7.43 (d, J = 12.5 Hz, 1H ),7.30-7.20(m,4H),5.29(p,J=7.2Hz,1H),3.76(t,J=6.7Hz,2H),3.14(brs,4H),2.81(brs,2H ), 2.70 (t, J = 6.8Hz, 2H), 2.67-2.55 (m, 3H), 2.42 (s, 3H), 1.51 (d, J = 7.0Hz, 3H), 1.37 (s, 9H) ppm. MS(ESI)m / z 776.8(M+H) + .
[0347] Embodiment 13
[0348] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-(propan-2-yl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1, 2,4-Oxadiazole-5-carboxamide
[0349] Example 13A
[0350] (S)-tert-Butyl 3-isopropyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0351] To a mixture of 5-fluoro-2-nitropyridine (467 mg, 3.28 mmol) in dimethyl sulfoxide (10 mL) under N2 at 20 ° C, (S)-3-isopropylpiperazine-1-carboxylic acid tert-butyl ester (500 mg, 2.190 mmol) and N, N-diisopropylethylamine (1.147 mL, 6.57 mmol) were added. The reaction mixture was stirred at 120 ° C for 16 hours. The mixture was cooled and poured into ice water (30 mL). The material in the mixture was collected by filtration. The material was ground in a mixture of ethyl acetate and petroleum ether to form a slurry. The slurry was filtered, and the filter cake was vacuum dried to obtain the title compound. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 8.25 (d, J = 3.00 Hz, 1H), 8.11 (d, J = 9.26 Hz, 1H), 7.46 (dd, J = 9.38, 3.00 Hz, 1H), 4.02-4.13 (m, 1H), 3.92 (br d, J = 12.26 Hz, 3H), 3.18 (br s, 1H), 2.84-3.10 (m, 2H), 2.01-2.15 (m, 1H), 1.41 (s, 9H), 1.05 (br d, J = 4.38 Hz, 3H), 0.73 (d, J = 6.75 Hz, 3H) ppm.
[0352] Example 13B
[0353] (S)-4-(6-Aminopyridin-3-yl)-3-isopropylpiperazine-1-carboxylic acid tert-butyl ester
[0354] To a mixture of Pd / C (10 wt %, 121 mg, 0.114 mmol) in ethyl acetate (12 mL) was added Example 13A (400 mg, 1.142 mmol) at ambient temperature. The mixture was hydrogenated using a hydrogen balloon for 2 hours. The mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to give the crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.66 (br s, 1H), 7.21 (br d, J = 7.75 Hz, 1H), 6.39 (d, J = 8.75 Hz, 1H), 5.49 (br s, 2H), 3.35-3.65 (m, 2H), 2.90 (br s, 3H), 2.51-2.54 (m, 2H), 1.77 (br s, 1H), 1.41 (s, 9H), 0.70-0.91 (m, 6H) ppm.
[0355] Example 13C
[0356] (S)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methyl tert-butyl 3-isopropylpiperazine-1-carboxylate
[0357] To a solution of Example 1M (200 mg, 0.49 mmol) in 1,4-dioxane (5 mL) was added Example 13B (233 mg, 0.73 mmol), Pd2(dba)3 (CAS 52409-22-0, 44 mg, 0.049 mmol), XantPhos (CAS161265-03-8, 28 mg, 0.049 mmol) and cesium carbonate (316 mg, 0.97 mmol). The mixture was degassed using a stream of nitrogen and stirred at 100 °C for 12 hours. The reaction mixture was cooled, diluted with ethyl acetate, and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography using tetrahydrofuran and petroleum ether to give the title compound. LC / MS (ESI+): m / z 684.5 (M+H) + .
[0358] Example 13D
[0359] 3-(tert-butyl)-N-((R)-1-(4-(6-((5-((S)-2-isopropylpiperazin-1-yl)pyridin-2-yl)amino) Pyrimidin-4-yl)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0360] To a solution of Example 13C (280 mg, 0.372 mmol) in 1,4-dioxane (3 mL) was added hydrochloric acid (4N in dioxane, 3 mL) dropwise at ambient temperature. The mixture was stirred for 1 hour and concentrated under reduced pressure to give the crude title compound as the hydrochloride salt. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.89 (s, 1H), 8.67 (s, 1H), 7.97 (br d,J=2.64Hz,2H),7.77-7.88(m,1H),7.74-7.89(m,1H),7.55-7.69(m,2H) ,7.21-7.43(m,2H),5.33(quin,J=7.12Hz,1H),3.21-3.31(m,3H),3.00-3. 11(m,1H),2.83-2.92(m,1H),2.62-2.82(m,3H),2.47(s,3H),1.51(d,J=6. 90Hz, 3H), 1.36 (s, 9H), 0.89 (d, J = 6.53Hz, 3H), 0.75 (d, J = 6.78Hz, 3H) ppm. LC / MS(ESI+):m / z 584.5(M+H) + .
[0361] Example 13E
[0362] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-(propan-2-yl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1, 2,4-Oxadiazole-5-carboxamide
[0363] To a solution of Example 13D (220 mg, 0.34 mmol) in acetonitrile (5 mL) was added Example 1J (175 mg, 0.51 mmol), sodium iodide (153 mg, 1.02 mmol) and N,N-diisopropylethylamine (296 μL, 1.70 mmol). The mixture was stirred at 80 °C for 16 hours. The mixture was cooled to ambient temperature, filtered, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Waters TM Xbridge C18 column, 30×100 mm×10 μm, 10 mM ammonium bicarbonate in water and acetonitrile as mobile phase). 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.35 (s, 1H), 9.86-10.00 (m, 2H), 8.68 (s, 1H), 8.00 (brd, J = 2.63 Hz, 2H), 7.82 (br s, 2H), 7.60 (br d, J = 8.55 Hz, 2H), 7.36-7.47 (m, 1H), 7.25 (q, J = 8.70 Hz, 4H), 5.27-5.39 (m, 1H), 3.69-3.80 (m, 2H), 3.38-3.43 (m, 2H), 3.09-3.20 (m, 1H), 2.88 (br s,1H),2.73-2.79(m,2H),2.67-2.71(m,2H),2.52(d,J=1.75Hz,2H),2.47(s,3H),2.28-2.35(m,2H),2. 17-2.26(m,2H),1.51(d,J=7.02Hz,3H),1.36(s,9H),0.89(d,J=6.58Hz,3H),0.76(d,J=6.80Hz,3H)ppm. MS(ESI)m / z 800.5(M+H) + .
[0364] Embodiment 14
[0365] 3-tert-butyl-N-[(1R)-1-{2-chloro-4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazine- 1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]phenyl}ethyl]-1,2,4-oxadiazole 5-Diazolecarboxamide
[0366] Example 14A
[0367] (S,E)-N-(4-bromo-2-chlorobenzylidene)-2-methylpropane-2-sulfenamide
[0368] A 1 L flask was charged with triisopropyl borate (139 g, 0.74 mol), 4-bromo-2-chlorobenzaldehyde (125 g, 0.57 mol) and (S)-2-methylpropane-2-sulfinamide (90 g, 0.74 mol) at ambient temperature. The mixture was stirred at 70 ° C for 12 hours. Water (0.5 L) was added, and the mixture was extracted with dichloromethane (0.5 L×3), washed with brine (1.0 L), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The reaction was repeated three times on the same scale. The crude material from all four batches was combined to obtain the title compound. MS (ESI) m / z 322.0,324.0 (M+H) + .
[0369] Example 14B
[0370] (S)-N-((R)-1-(4-bromo-2-chlorophenyl)ethyl)-2-methylpropane-2-sulfenamide
[0371] A 5 L reactor was charged with dichloromethane (3.5 L) and Example 14A (173 g, 0.53 mol). The mixture was refrigerated at 0 ° C. CH3MgBr (3.0 M in tetrahydrofuran, 268 mL, 0.80 mol) was added dropwise at 0 ° C. The mixture was stirred at ambient temperature for 12 hours. The reaction mixture was refrigerated in an ice bath, and saturated aqueous NH4Cl solution (1.6 L) was added to the mixture. The organic phase was separated, and the aqueous phase was extracted with dichloromethane (0.5 L×3). The reaction was repeated four times on the same scale. The combined organic layers were washed with brine (5.5 L), dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was triturated in hexanes to give the crude title compound. MS (ESI) m / z 338.0,340.0 (M+H) + .
[0372] Example 14C
[0373] (S)-N-((R)-1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) Ethyl)-2-methylpropane-2-sulfenamide
[0374] To a solution of Example 14B (15.0 g, 40.0 mmol) in 1,4-dioxane (150 mL) was added bis(pinacolato)diboron (10.1 g, 40.0 mmol) and potassium acetate (7.82 g, 80.0 mmol) at 20°C. The reactor was evacuated and backfilled with nitrogen three times, and 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (3.26 g, 4.0 mmol) was added. The reaction vessel was evacuated and backfilled with nitrogen three times again. The reaction mixture was heated to 110°C and stirred for 16 hours. The reaction mixture was cooled and filtered through a pad of celite. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography by eluting with petroleum ether and ethyl acetate to give the title compound. MS (ESI) m / z 386.2 (M+H) + .
[0375] Example 14D
[0376] (R)-1-(2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-amine To a solution of Example 14C (8.00 g, 20.7 mmol) in 1,4-dioxane (100 mL) was added hydrochloric acid (4N in 1,4-dioxane, 100 mL) dropwise at ambient temperature. The mixture was stirred for 2 hours and concentrated under reduced pressure to give the crude title compound as the hydrochloride salt. MS (ESI) m / z 282.3 (M+H) + .
[0377] Example 14E
[0378] (R)-3-(tert-butyl)-N-(1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- (2-(4-(2-(4-(2-(4-(2-(phenyl)-1-yl)-2-(ethyl)-1-(2-(4 ...
[0379] Triethylamine (17.4 mL, 125 mmol) was added to a solution of Example 14D (6.60 g, 20.8 mmol) and 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid methyl ester (7.64 g, 41.5 mmol) in ethanol (180 mL) at 20 °C. The mixture was stirred at 80 °C for 12 hours and then concentrated under reduced pressure to remove ethanol. The crude material was purified by silica gel column chromatography, eluted with petroleum ether and ethyl acetate to obtain the title compound. 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.95 (d, J = 7.5 Hz, 1H), 7.65-7.56 (m, 3H), 5.42 (quin, J = 7.2 Hz, 1H), 1.48 (d, J = 7.1 Hz, 3H), 1.36 (s, 9H), 1.28 (s, 12H) ppm. MS (ESI) m / z 434.4 (M+H) + .
[0380] Example 14F
[0381] (R)-3-(tert-butyl)-N-(1-(4-(6-chloropyrimidin-4-yl)-2-chlorophenyl)ethyl)-1,2,4-oxadiazole-5- Formamide
[0382] To a mixture of Example 14E (6.00 g, 13.83 mmol) and 4,6-dichloropyrimidine (2.47 g, 16.60 mmol) in 1,4-dioxane (111 mL) and water (28 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.13 g, 1.38 mmol) and potassium phosphate (5.87 g, 27.7 mmol). The mixture was degassed using a stream of nitrogen at ambient temperature and stirred at 80 °C for 1 hour under a nitrogen atmosphere. The mixture was cooled, poured into water and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluted with ethyl acetate in hexane to obtain the crude title compound. 1 H NMR (400MHz, dimethyl sulfoxide-d6): δppm 10.02 (br d,J=7.63Hz,1H),9.11(d,J=0.63Hz,1H),8.39(d,J=0.75Hz,1H),8.31(d,J=1.63Hz,1H),8.23(dd,J=8.2 5,1.63Hz,1H),7.74(d,J=8.25Hz,1H),5.47(brt,J=7.19Hz,1H),1.53(d,J=7.00Hz,3H),1.37(s,9H)ppm. MS(ESI)m / z420.1,422.1(M+H) + .
[0383] Example 14G
[0384] (S)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-chloro tert-butyl 3-(phenyl)pyrimidin-4-yl)amino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate
[0385] To a solution of Example 14H (288 mg, 0.69 mmol) in 1,4-dioxane (6.4 mL) was added Example 1L (240 mg, 0.82 mmol), Pd2(dba)3 (CAS 52409-22-0, 38 mg, 0.04 mmol), XantPhos (CAS161265-03-8, 40 mg, 0.07 mmol) and cesium carbonate (447 mg, 1.37 mmol). The mixture was degassed using a stream of nitrogen and stirred at 100 °C for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled, diluted with ethyl acetate, filtered through diatomaceous earth, concentrated under reduced pressure and purified by silica gel chromatography using ethyl acetate and petroleum ether to obtain the title compound. 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.97-10.11 (m, 2H), 7.92-8.11 (m, 4H), 7.72 (d, J = 8.11 Hz, 2H), 7.44 (dd, J = 9.12, 2.80 Hz, 1H), 5.46 (m, 1H), 3.75-3.89 (m, 2H), 3.61 (brd, J = 11.09 Hz, 1H), 3.17 (brd, J = 11.80 Hz, 3H), 2.90-3.00 (m, 1H), 1.53 (d, J = 7.03 Hz, 3H), 1.41 (s, 9H), 1.37 (s, 9H), 0.88 (d, J = 6.32 Hz, 3H) ppm. LC / MS(ESI+):m / z 676.4(M+H) + .
[0386] Example 14H
[0387] 3-(tert-butyl)-N-((R)-1-(2-chloro-4-(6-((5-((S)-2-methylpiperazin-1-yl)pyridin-2-yl)amino 4-(2-(4-yl)pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0388] Hydrochloric acid (4N in 1,4-dioxane, 3mL) is added dropwise to a solution of Example 14G (258mg, 0.38mmol) in 1,4-dioxane (3mL). The reaction mixture is stirred at ambient temperature for 1 hour. The reaction mixture is concentrated under reduced pressure, dissolved in water (10mL), and alkalized with a saturated aqueous sodium bicarbonate solution to adjust the pH to 8. The mixture is extracted with dichloromethane (10mL, three times), and the combined organic phase is washed with brine (10mL), dried over sodium sulfate and filtered. The filtrate is concentrated under reduced pressure to obtain the title compound. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.08 (br s, 2H), 8.72 (s, 1H), 7.91-8.10 (m, 4H), 7.71 (br d, J=8.13 Hz, 2H), 7.40 (br dd, J=9.13, 2.75 Hz, 2H), 5.46 (br s, 1H), 3.64-3.80 (m, 1H), 3.01-3.15 (m, 1H), 2.79-2.98 (m, 3H), 2.62-2.77 (m, 2H), 1.53 (br d, J=6.88 Hz, 3H), 1.36 (s, 9H), 0.95 (d, J=6.38 Hz, 3H) ppm. LC / MS(ESI+):m / z 576.3(M+H) + .
[0389] Example 14I
[0390] 3-tert-butyl-N-[(1R)-1-{2-chloro-4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazine- 1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]phenyl}ethyl]-1,2,4-oxadiazole 5-Diazolecarboxamide
[0391] To a solution of Example 14H (85 mg, 0.15 mmol) in acetonitrile (2 mL) was added Example 1J (102 mg, 0.30 mmol), sodium iodide (66 mg, 0.44 mmol) and N,N-diisopropylethylamine (129 μL, 0.74 mmol). The mixture was stirred at 80 °C for 16 hours. The mixture was cooled to ambient temperature, filtered, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex C18 column, 30×75 mm×3 μm, 0.1% formic acid in water and acetonitrile as mobile phase). 1 HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.34 (s, 1H), 9.97-10.13 (m, 2H), 8.73 (s, 1H), 7.91-8.11 (m, 4H), 7.72 (br d, J = 8.13 Hz, 2H), 7.47 (br d,J=8.00Hz,1H),7.20-7.33(m,4H),5.46(quin,J=7.10Hz,1H),3.80-3.95(m,1H),3.76(t,J=6.63Hz,2H ),3.16-3.26(m,2H),2.95-3.10(m,2H),2.57-2.93(m,8H),1.53(d,J=7.00Hz,3H),1.37(s,9H),1.00(br d,J=6.00Hz,3H)ppm. MS(ESI)m / z 792.2(M+H) + .
[0392] Embodiment 15
[0393] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-(methoxymethyl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl 1,2,4-oxadiazole-5-carboxamide
[0394] Example 15A
[0395] (R)-2-(Hydroxymethyl)piperazine-1,4-dicarboxylic acid 1-benzyl 4-tert-butyl ester
[0396] To a solution of (R)-3-(hydroxymethyl)piperazine-1-carboxylic acid tert-butyl ester (1.5 g, 6.94 mmol) in tetrahydrofuran (30 mL) was added sodium carbonate (2.205 g, 20.81 mmol) in water (6.00 mL) at 20°C. Benzyl chloroformate (1.775 g, 10.40 mmol) was added dropwise at 0°C. The reaction mixture was extracted with ethyl acetate (three times), washed with brine, dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using ethyl acetate in petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.28-7.39 (m, 5H), 5.09 (s, 2H), 4.82 (brt, J = 4.63 Hz, 1H), 3.97 (brd, J = 13.63 Hz, 1H), 3.80 (brd, J = 12.76 Hz, 2H), 3.34-3.49 (m, 2H), 2.68-3.07 (m, 4H), 1.99 (s, 1H), 1.40 (s, 9H), 1.17 (t, J = 7.07 Hz, 1H) ppm. MS (ESI) m / z 295.2 (M-tBu+H) + .
[0397] Example 15B
[0398] (R)-2-(Methoxymethyl)piperazine-1,4-dicarboxylic acid 1-benzyl 4-tert-butyl ester
[0399] Example 15A (2.0 g, 5.71 mmol) was dissolved in dichloromethane (40 mL), and the mixture was refrigerated to 0 ° C. 1,8-bis (dimethylamino) naphthalene (4.89 g, 22.83 mmol) was added to the mixture at one time, and then trimethyloxonium tetrafluoroborate (3.38 g, 22.83 mmol) was slowly added within 5 minutes. The mixture was stirred at 0 ° C for 30 minutes, warmed to 20 ° C, and stirred for 1 hour. The reaction mixture was extracted with ethyl acetate (five times). The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using ethyl acetate in petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.27-7.40 (m, 4H), 5.01-5.17 (m, 2H), 4.18 (brd, J=0.88 Hz, 1H), 3.68-3.97 (m, 3H), 3.32 (d, J=2.26 Hz, 2H), 3.24 (brs, 3H), 2.68-3.04 (m, 3H), 1.40 (s, 9H) ppm.
[0400] Example 15C
[0401] (R)-tert-Butyl 3-(methoxymethyl)piperazine-1-carboxylate
[0402] To a suspension of Pd / C (10 wt %, 0.38 g, 0.357 mmol) in ethyl acetate (26 mL) was added Example 15B (1.3 g, 3.57 mmol). The reaction mixture was hydrogenated at ambient temperature for 16 hours using a hydrogen balloon. The mixture was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure to give the crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 3.65-3.87 (m, 2H), 3.26 (s, 3H), 3.20-3.22 (m, 1H), 3.22 (d, J=6.02 Hz, 1H), 2.83 (br d, J=11.80 Hz, 1H), 2.59-2.77 (m, 2H), 2.46-2.56 (m, 2H), 2.30 (br s, 1H), 1.40 (s, 9H) ppm.
[0403] Example 15D
[0404] (R)-tert-Butyl 3-(methoxymethyl)-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
[0405] To a mixture of 5-fluoro-2-nitropyridine (740 mg, 5.21 mmol) in dimethyl sulfoxide (16 mL) was added Example 15C (800 mg, 3.47 mmol) and N,N-diisopropylethylamine (1.820 mL, 10.42 mmol) at ambient temperature. The reaction mixture was heated to 120 ° C and stirred for 12 hours. The reaction mixture was cooled and poured into water, and the mixture was extracted with ethyl acetate (twice). The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using ethyl acetate in petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 8.64 (d, J = 2.88 Hz, 1H), 8.44 (d, J = 8.88 Hz, 1H), 8.22 (d, J = 3.00 Hz, 1H), 8.16 (d, J = 9.26 Hz, 1H), 8.04 (dd, J = 8.94, 2.81 Hz, 1H), 7.44 (dd, J = 9.26, 3.00 Hz, 1H), 4.34 (br s, 1H), 3.96-4.07 (m, 1H), 3.90 (br d,J=1.63Hz,1H),3.80(brd,J=12.88Hz,1H),3.36-3.48(m,2H),3.32(s,1H),3.23(s,5H),1.42(s,9H)ppm. MS(ESI)m / z 353.3(M+H) + .
[0406] Example 15E
[0407] (R)-tert-Butyl 4-(6-aminopyridin-3-yl)-3-(methoxymethyl)piperazine-1-carboxylate
[0408] To a suspension of Pd / C (10 wt %, 362 mg, 0.341 mmol) in ethyl acetate (36 mL) was added Example 15D (1.2 g, 3.41 mmol). The reaction mixture was hydrogenated at ambient temperature for 16 hours using a hydrogen balloon. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated under reduced pressure to give the crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.62 (d, J = 2.63 Hz, 1H), 7.21 (dd, J = 8.76, 2.50 Hz, 1H), 6.40 (d, J = 8.76 Hz, 1H), 5.51 (br s, 2H), 3.39-3.69 (m, 3H), 3.01-3.18 (m, 5H), 2.72-2.94 (m, 2H), 1.41 (s, 9H) ppm.
[0409] Example 15F
[0410] (R)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-methyl tert-butyl 3-(((((((((((((((((((((((- ...
[0411] To a solution of Example 1E (300 mg, 0.75 mmol) in 1,4-dioxane (5 mL) was added Example 15E (363 mg, 1.13 mmol), Pd2(dba)3 (CAS 52409-22-0, 69 mg, 0.075 mmol), XantPhos (CAS161265-03-8, 43 mg, 0.075 mmol) and cesium carbonate (489 mg, 1.50 mmol). The mixture was degassed using an argon stream and stirred at 100 ° C for 12 hours. The reaction mixture was cooled, diluted with ethyl acetate, filtered through diatomaceous earth, concentrated under reduced pressure and purified by silica gel chromatography using ethyl acetate and petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.02 (s, 1H), 9.91 (d, J = 7.89 Hz, 1H), 8.70 (s, 1H), 8.02 (br d,J=2.85Hz,1H),7.79-7.87(m,2H),7.65-7.74(m,1H),7.60(d,J=8.55 Hz,1H),7.46(dd,J=9.21,2.63Hz,1H),7.25-7.35(m,1H),5.24-5.39(m, 1H),3.69-4.00(m,3H),3.24-3.33(m,2H),3.20(brs,5H),2.89-3.10(m ,2H),2.47(s,3H),1.51(d,J=6.80Hz,3H),1.42(s,9H),1.36(s,9H)ppm. LC / MS(ESI+):m / z 686.5(M+H) + .
[0412] Example 15G
[0413] 3-(tert-butyl)-N-((R)-1-(4-(6-((5-((R)-2-(methoxymethyl)piperazin-1-yl)pyridin-2-yl) (amino)pyrimidin-4-yl)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0414] To a solution of Example 15F (450 mg, 0.66 mmol) in 1,4-dioxane (3 mL) was added hydrochloric acid (4N in dioxane, 3 mL) dropwise at ambient temperature. The mixture was stirred for 1 hour and concentrated under reduced pressure to give the crude title compound as the hydrochloride salt. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.97 (s, 1H), 9.91 (br d, J = 8.11 Hz, 1H), 8.69 (s, 1H), 7.95-8.00 (m, 1H), 7.80-7.86 (m, 2H), 7.55-7.70 (m, 2H), 7.38-7.43 (m, 1H), 7.27-7.34 (m, 1H), 5.27-5.38 (m, 1H), 3.67-3.81 (m, 2H), 3.56 (s, 6H), 3.51-3.61 (m, 1 H),3.34(s,3H),3.14-3.20(m,3H),3.12-3.20(m,1H),2.92-3.05(m,1H),2.90-3.03(m,1H),2.7 8-2.86(m,1H),2.65-2.74(m,1H),2.47(s,3H),1.51(brd,J=6.80Hz,3H),1.33-1.39(m,9H)ppm. LC / MS(ESI+):m / z 586.4(M+H) + .
[0415] Example 15H
[0416] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-(methoxymethyl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl 1,2,4-oxadiazole-5-carboxamide
[0417] Example 15G (130 mg, 0.22 mmol), Example 1J (115 mg, 0.33 mmol), N,N-diisopropylethylamine (194 μL, 1.11 mmol) and sodium iodide (100 mg, 0.66 mmol) were mixed in acetonitrile (5 mL). The mixture was stirred at 80 °C for 16 hours. The mixture was cooled, quenched with a few drops of formic acid, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex C18 column, 30×75 mm×3 μm, 0.1% formic acid in water and acetonitrile as mobile phase). 1HNMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.33 (s, 1H), 9.96 (s, 1H), 9.88 (brd, J = 7.65 Hz, 1H), 8.70 (s, 1H), 8.14 (s, 1H), 8.00 (brd, J = 2.38 Hz, 2H), 7.76-7.91 (m, 2H), 7.64-7.73 (m, 1H), 7.60 (br d, J = 8.66 Hz, 1H), 7.44 (br dd,J=8.91,2.64Hz,1H),7.18-7.31(m,4H),5.33(quin,J=7.09Hz,1H),3.85-3.96(m,1H),3.76(t,J=6.65Hz,2H),3.51-3.68(m,1H),3.29(br s,1H),3.17(s,3H),2.85-3.08(m,3H),2.73-2.82(m,2H),2.69(br t,J=6.65Hz,2H),2.51-2.63(m,3H),2.47(s,3H),2.17-2.34(m,2H),1.51(br d,J=6.90Hz,3H),1.36(s,9H)ppm. MS (ESI) m / z 802.3 (M+H) + .
[0418] Example 16
[0419] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-(trifluoromethyl)phenyl}ethyl]- 1,2,4-Oxadiazole-5-carboxamide
[0420] Example 16A
[0421] (S,E)-N-(4-bromo-2-(trifluoromethyl)benzylidene)-2-methylpropane-2-sulfenamide
[0422] Into a 500mL flask, 4-bromo-2-(trifluoromethyl)benzaldehyde (10.00g, 39.5mmol) and dichloromethane (100mL) are loaded. In the stirred mixture, (S)-2-methylpropane-2-sulfinamide (6.23g, 51.4mmol) is added at ambient temperature, and then titanium (IV) (18.03g, 79.0mmol) is added. The mixture is stirred at 30°C for 12 hours, and quenched with ethyl acetate (50mL) and water (50mL). The mixture is filtered, and the organic phase is separated. The organic phase is extracted with ethyl acetate (100mL, three times), and the organic phase merged is dried over sodium sulfate and filtered. The filtrate is concentrated under reduced pressure to obtain the thick title compound. 1H NMR (400MHz, CDCl3): δppm 8.89(d,J=1.5Hz,1H), 8.09(d,J=8.4Hz,1H), 7.91(d,J=1.3Hz,1H), 7.79(d,J=8.4Hz,1H), 1.31-1.21(m,9H)ppm.
[0423] Example 16B
[0424] (S)-N-((R)-1-(4-bromo-2-(trifluoromethyl)phenyl)ethyl)-2-methylpropane-2-sulfenamide
[0425] Into a 250mL flask, anhydrous toluene (60mL) and Example 16A (5.40g, 15.16mmol) are loaded. The mixture is refrigerated to -5°C. CH3MgBr (3.0M in tetrahydrofuran, 10.1mL, 30.3mmol) is added dropwise. The mixture is then stirred at 0°C for 3 hours, and saturated aqueous NH4Cl solution (120mL) is added to quench the reaction. The organic phase is separated, and the aqueous phase is extracted with ethyl acetate (30mL, three times). The combined organic layer is washed with brine (30mL), dried over sodium sulfate, and filtered. The filtrate is concentrated under reduced pressure, and the residue is purified by silica gel column chromatography using ethyl acetate and petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide): δ ppm 7.92 (dd, J = 8.50, 1.75 Hz, 1H), 7.81 (d, J = 1.88 Hz, 1H), 7.74 (d, J = 8.50 Hz, 1H), 5.63 (d, J = 4.50 Hz, 1H), 4.69 (quin, J = 5.78 Hz, 1H), 1.44 (d, J = 6.63 Hz, 3H), 1.06 (s, 9H) ppm. MS (ESI) m / z 372.0, 374.0 (M+H) + .
[0426] Example 16C
[0427] (S)-N-((R)-1-(2-trifluoromethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl)ethyl)-2-methylpropane-2-sulfenamide
[0428] To a solution of Example 16B (1.00 g, 2.69 mmol) in 1,4-dioxane (20 mL) was added bis(pinacolato)diboron (853 mg, 3.36 mmol) and potassium acetate (527 mg, 5.37 mmol) at 20 °C. The reactor was evacuated and backfilled with nitrogen three times, and then 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (197 mg, 0.27 mmol) was added. The reaction vessel was evacuated and backfilled with nitrogen three times again. The reaction mixture was heated to 80 °C and stirred for 16 hours. The reaction mixture was cooled and filtered through a diatomaceous earth pad. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, by eluting with petroleum ether and ethyl acetate to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 7.93 (br d, J = 6.58 Hz, 1H), 7.71-7.89 (m, 2H), 5.62 (brd, J = 3.73 Hz, 1H), 4.66-4.82 (m, 1H), 1.45 (br d, J = 6.14 Hz, 3H), 1.30 (s, 9H), 1.06 (brd, J = 2.19 Hz, 12H) ppm. MS (ESI) m / z 420.2 (M+H) + .
[0429] Example 16D
[0430] (R)-1-(2-Trifluoromethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) Ethyl-1-amine
[0431] To a solution of Example 16C (900 mg, 2.15 mmol) in 1,4-dioxane (5 mL) was added hydrochloric acid (4N in 1,4-dioxane, 10 mL) dropwise at ambient temperature. The mixture was stirred for 1 hour and then concentrated under reduced pressure to give the crude title compound as the hydrochloride salt. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): 8.94 (br s, 3H), 8.01-8.15 (m, 2H), 7.93 (s, 1H), 4.52 (br d, J = 4.75 Hz, 1H), 1.54 (d, J = 6.63 Hz, 3H), 1.31 (s, 12H) ppm. MS (ESI) m / z 316.2 (M+H) + .
[0432] Example 16E
[0433] (R)-3-(tert-butyl)-N-(1-(2-trifluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2-(4-(2-((4-((2-( ...
[0434] Triethylamine (622 mg, 6.14 mmol) was added to Example 16D (360 mg, 1.02 mmol) and 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid methyl ester (471 mg, 2.56 mmol) in ethanol (8 mL) solution at 20 ° C. The mixture was stirred at 60 ° C for 16 hours, and then concentrated under reduced pressure to remove ethanol. The crude material was purified by silica gel column chromatography, eluted with petroleum ether and ethyl acetate to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.04 (d, J = 7.23 Hz, 1H), 7.93-8.00 (m, 1H), 7.84-7.92 (m, 2H), 5.40 (quin, J = 6.91 Hz, 1H), 1.49 (d, J = 6.80 Hz, 3H), 1.36 (s, 9H), 1.30 (s, 12H) ppm. MS (ESI) m / z 468.2 (M+H) + .
[0435] Example 16F
[0436] (R)-3-(tert-butyl)-N-(1-(4-(6-chloropyrimidin-4-yl)-2-(trifluoromethyl)phenyl)ethyl)-1,2,4- Oxadiazole-5-carboxamide
[0437] To a mixture of Example 16E (230 mg, 0.49 mmol) and 4,6-dichloropyrimidine (147 mg, 0.98 mmol) in tetrahydrofuran (10 mL) was added a solution of potassium phosphate (209 mg, 0.98 mmol) in water (2.5 mL) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (22 mg, 0.03 mmol). The mixture was degassed using a stream of nitrogen at ambient temperature and stirred at 80 °C for 2 hours under a nitrogen atmosphere. The mixture was cooled, poured into water and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluted with ethyl acetate in hexane to obtain the crude title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.10 (br d, J = 7.23 Hz, 1H), 9.14 (s, 1H), 8.52-8.59 (m, 2H), 8.49 (s, 1H), 8.06 (d, J = 8.11 Hz, 1H), 5.45 (br t, J = 6.91 Hz, 1H), 1.55 (d, J = 6.80 Hz, 3H), 1.37 (d, J = 1.32 Hz, 9H) ppm. MS (ESI) m / z 454.1 (M+H) + .
[0438] Example 16G
[0439] (S)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3- tert-butyl (trifluoromethyl)phenyl)pyrimidin-4-yl)amino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate
[0440] To a solution of Example 16F (170 mg, 0.38 mmol) in 1,4-dioxane (4 mL) was added Example 1L (138 mg, 0.45 mmol), Pd2(dba)3 (CAS 52409-22-0, 21 mg, 0.022 mmol), XantPhos (CAS161265-03-8, 22 mg, 0.037 mmol) and cesium carbonate (244 mg, 0.75 mmol). The mixture was degassed using a stream of nitrogen and stirred at 100 °C for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled, diluted with ethyl acetate, and filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography using ethyl acetate and petroleum ether to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 10.24 (br s, 1H), 10.10 (d, J = 7.23 Hz, 1H), 8.78 (s, 1H), 8.34 (s, 1H), 8.29 (brd, J = 8.33 Hz, 1H), 7.99-8.07 (m, 2H), 7.67-7.78 (m, 1H), 7.49 (brdd, J = 8.99, 2.41 Hz, 1H), 7.25-7.35 (m, 1H), 5.45 (brt, J = 7.13 Hz, 1H), 3.77-3.92 (m, 2H), 3.56-3.69 (m, 1H), 3.26-3.37 (m, 1H), 3.19 (br d,J=11.18Hz,2H),2.91-3.01(m,1H),1.56(brd,J=6.80Hz,3H),1.42(s,9H),1.37(s,9H),0.89(d,J=6.58Hz,3H)ppm. LC / MS(ESI+):m / z 710.4(M+H) + .
[0441] Example 16H
[0442] 3-(tert-butyl)-N-((R)-1-(2-trifluoromethyl-4-(6-((5-((S)-2-methylpiperazin-1-yl)pyridine-2-yl) 4-(4-yl)amino)pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0443] To a solution of Example 16G (100 mg, 0.14 mmol) in methanol (20 mL) was added hydrochloric acid (4 N in methanol, 20 mL) dropwise. The reaction mixture was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to give the crude title compound as the hydrochloride salt. 1H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 9.99-10.17 (m, 2H), 8.75 (s, 1H), 8.35 (s, 1H), 8.28 (brd, J = 8.25 Hz, 1H), 7.93-8.18 (m, 3H), 7.65-7.78 (m, 1H), 7.41 (dd, J = 9.13, 2.75 Hz, 1H), 7.22-7.35 (m, 1H), 5.45 (quin, J = 6.69Hz,1H),3.68-3.78(m,1H),3.18-3.35(m,1H),3.01-3.12(m,1H),2.81-2.98(m,3H ),2.66-2.77(m,2H),1.55(brd,J=6.88Hz,3H),1.37(s,9H),0.96(d,J=6.38Hz,3H)ppm. LC / MS(ESI+):m / z 610.3(M+H) + .
[0444] Example 16I
[0445] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-(trifluoromethyl)phenyl}ethyl]- 1,2,4-Oxadiazole-5-carboxamide
[0446] To a solution of Example 16H (63 mg, 0.11 mmol) in acetonitrile (2 mL) was added Example 1J (56 mg, 0.16 mmol), sodium iodide (65 mg, 0.43 mmol) and N,N-diisopropylethylamine (56 μL, 0.32 mmol). The mixture was stirred at 80 °C for 16 hours. The mixture was cooled to ambient temperature, filtered, and directly subjected to reverse phase preparative HPLC to isolate the title compound (Waters TM Xbridge C18 column, 30×100 mm×10 μm, 10 mM ammonium bicarbonate in water and acetonitrile as mobile phase). 1H NMR (400MHz, dimethyl sulfoxide-d6): δppm 10.34(br s,1H),10.10(s,2H),8.75(s,1H),8.35(s,1H),8.28(br d,J=8.25Hz,1H),8.10(br s,1H),8.02(brd,J=10.38Hz,2H),7.72(br s,1H),7.39-7.54(m,1H),7.17-7.33(m,4H),5.45(br d,J=5.88Hz,1H),3.88(br d,J=5.13Hz,1H),3.76(brt,J=6.57Hz,2H),3.22(br d,J=11.88Hz,1H),2.99(br t,J=9.38Hz,1H),2.86(br d,J=10.76Hz,1H),2.78(br t,J=7.32Hz,2H),2.66-2.73(m,4H),2.44(br d, J=11.63Hz, 2H), 2.31 (brd, J=11.63Hz, 1H), 1.56 (br d, J=6.75Hz, 3H), 1.37 (s, 9H), 0.99 (br d, J=6.25Hz, 3H) ppm. MS(ESI)m / z 826.4(M+H) + .
[0447] Embodiment 17
[0448] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-fluorophenyl}ethyl]-1,2,4-oxadiazole 5-Diazolecarboxamide
[0449] Example 17A
[0450] (S,E)-N-(4-Bromo-2-fluorobenzylidene)-2-methylpropane-2-sulfenamide
[0451] Triisopropyl borate (243g, 1.29mol), 4-bromo-2-fluorobenzaldehyde (250g, 1.23mol) and (S)-2-methylpropane-2-sulfinamide (179g, 1.48mol) were loaded into a 1L reactor at ambient temperature. The mixture was stirred at 70°C for 12 hours. Water (500mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (500mL×3). The combined organic phase was washed with brine (1.0L), dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the title compound. 1 HNMR (400MHz, CDCl3): δppm8.82(s,1H),7.81-8.92(m,1H),7.30-7.47(m,2H),1.26(s,9H)ppm.
[0452] Example 17B
[0453] (S)-N-((R)-1-(4-bromo-2-fluorophenyl)ethyl)-2-methylpropane-2-sulfenamide
[0454] Anhydrous dichloromethane (3.0L) and Example 16A (150g, 0.49mol) were loaded into a 5L reactor. The mixture was refrigerated to 0°C. CH3MgBr (3.0M in tetrahydrofuran, 245mL, 0.73mmol) was added dropwise. The mixture was warmed to ambient temperature and stirred for 12 hours, and then saturated aqueous NH4Cl solution (1.0L) was added to quench the reaction. The organic phase was separated, and the aqueous phase was extracted with dichloromethane (1.0L, three times). The combined organic layer was washed with brine (2.0L), dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain the crude title compound. 1 H NMR (400MHz, CDCl3): δppm 7.21-7.28(m,3H), 4.73-4.90(m,1H), 3.33(d,J=4.03Hz,1H), 1.56(d,J=6.85Hz,3H), 1.20(s,9H)ppm.
[0455] Example 17C
[0456] (R)-1-(4-Bromo-2-fluorophenyl)ethan-1-amine
[0457] A 1 L reactor was charged with Example 17B (87.0 g, 0.27 mol) and methanol (870 mL). To the stirred solution was added hydrochloric acid (4N in methanol, 435 mL, 1.74 mol) at 0°C. The reaction mixture was stirred at 0°C for 2 hours and concentrated to dryness under reduced pressure to give the crude title compound as the hydrochloride salt. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): δ ppm 8.80 (s, 3H), 7.59-7.76 (m, 2H), 7.53 (dd, J=8.38, 1.41 Hz, 1H), 4.41-4.63 (m, 1H), 1.44-1.57 (m, 3H) ppm.
[0458] Example 17D
[0459] (R)-tert-Butyl (1-(4-bromo-2-fluorophenyl)ethyl)carbamate
[0460] Into 3L reactor, load Example 17C (65.0g, 0.30mol), tetrahydrofuran (650mL) and water (650mL). At 0 ℃, add sodium hydroxide (35.8g, 0.89mol) and di-tert-butyl decarbonate (78.1g, 0.36mol) to the stirred solution. The reaction is warmed to ambient temperature and stirred for 2 hours. The mixture is diluted with water (1.0L), and the mixture is extracted with ethyl acetate (1.0L, three times). The combined organic layer is washed with brine (2.0L), dried over sodium sulfate and filtered. The filtrate is concentrated under reduced pressure, and the residue is purified by silica gel column chromatography with ethyl acetate and petroleum to obtain the title compound. 1 H NMR (400MHz, CD3OD): δppm 7.18-7.39(m,3H), 4.88-4.95(m,1H), 1.28-1.49(m,12H)ppm.
[0461] Example 17E
[0462] (R)-(1-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)amino tert-Butyl formate
[0463] To a solution of Example 17D (76.0 g, 0.24 mol) in 1,4-dioxane (760 mL) was added bis(pinacolato)diboron (72.8 g, 0.29 mol) and potassium acetate (46.9 g, 0.48 mol) at 20 °C. The reactor was evacuated and backfilled with nitrogen three times, and then 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (17.5 g, 0.02 mol) was added. The reaction vessel was evacuated and backfilled with nitrogen three times again. The reaction mixture was heated to 100 °C and stirred for 16 hours under a nitrogen atmosphere. The reaction mixture was cooled and filtered through a diatomaceous earth pad. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluted with petroleum ether and ethyl acetate to obtain the title compound. 1 HNMR (400MHz, CDCl3): δppm7.54(d,J=7.50Hz,1H),7.45(d,J=11.03Hz,1H),7.28-7.32(m,1H),4.99(s,2H),1.42(s,12H),1.34(s,12H)ppm.
[0464] Example 17F
[0465] (R)-1-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethan-1-amine
[0466] To a solution of Example 17E (1030 mg, 2.15 mmol) in dichloromethane (20 mL) was added hydrochloric acid (4N in 1,4-dioxane, 14 mL) dropwise at ambient temperature. The mixture was stirred for 3 hours and concentrated under reduced pressure to give the crude title compound as the hydrochloride salt. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): 8.68 (br s, 3H), 7.64-7.72 (m, 1H), 7.56 (d, J = 7.58 Hz, 1H), 7.40 (d, J = 10.64, 1H), 4.62 (brs, 1H), 1.52 (d, J = 6.85 Hz, 3H), 1.31 (s, 12H) ppm. MS (ESI) m / z 249.2 (M+H) + .
[0467] Example 17G
[0468] (R)-3-(tert-butyl)-N-(1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- (2-(4-(2-(4-(2-(4-(2-(phenyl)-1-yl)-2-(ethyl)-1-(2-(4 ...
[0469] To a solution of Example 17F (850 mg, 2.82 mmol) and 3-(tert-butyl)-1,2,4-oxadiazole-5-carboxylic acid methyl ester (779 mg, 4.23 mmol) in 2-methyltetrahydrofuran (10 mL) was added 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU, 1.28 mL, 8.46 mmol) at ambient temperature. The mixture was stirred for 2 hours and then diluted with ethyl acetate (50 mL) and brine (20 mL). The organic phase was separated and the aqueous phase was extracted with ethyl acetate (20 mL). The combined organic phase was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluted with hexane and ethyl acetate to obtain the title compound. 1 H NMR (400 MHz, dimethyl sulfoxide-d6): 9.95 (d, J = 7.70 Hz, 1H), 7.49-7.63 (m, 2H), 7.39 (d, J = 10.64 Hz, 1H), 5.42 (t, J = 7.27 Hz, 1H), 1.56 (d, J = 6.97 Hz, 3H), 1.42 (s, 9H), 1.35 (s, 12H) ppm. MS (ESI) m / z 418.2 (M+H) + .
[0470] Example 17H
[0471] (R)-3-(tert-butyl)-N-(1-(4-(6-chloropyrimidin-4-yl)-2-fluorophenyl)ethyl)-1,2,4-oxadiazole-5-yl Formamide
[0472] To a mixture of Example 17G (762 mg, 1.83 mmol) and 4,6-dichloropyrimidine (326 mg, 2.19 mmol) in 1,4-dioxane (7.3 mL) was added a solution of potassium phosphate (775 mg, 3.65 mmol) in water (2 mL) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (149 mg, 0.18 mmol). The mixture was degassed using a stream of nitrogen at ambient temperature and stirred at 85 °C for 20 minutes under a nitrogen atmosphere. The mixture was cooled, poured into water and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluting with ethyl acetate in hexanes to give the crude title compound. MS (ESI) m / z 404.1 (M+H) + .
[0473] Example 17I
[0474] (S)-4-(6-((6-(4-((R)-1-(3-(tert-butyl)-1,2,4-oxadiazole-5-carboxamido)ethyl)-3-fluoro tert-butyl 3-(phenyl)pyrimidin-4-yl)amino)pyridin-3-yl)-3-methylpiperazine-1-carboxylate
[0475] To a solution of Example 17G (268 mg, 0.66 mmol) in 1,4-dioxane (10 mL) was added Example 1L (349 mg, 1.20 mmol), racemic BINAP-Pd-G3 (CAS 2151915-22-7, 66 mg, 0.066 mmol) and cesium carbonate (649 mg, 1.99 mmol). The mixture was heated at 75 °C for 40 minutes under a nitrogen atmosphere. The mixture was cooled, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified using silica gel chromatography with ethyl acetate and hexanes to isolate the title compound. LC / MS (ESI+): m / z 660.4 (M+H) + .
[0476] Example 17J
[0477] 3-(tert-butyl)-N-((R)-1-(2-fluoro-4-(6-((5-((S)-2-methylpiperazin-1-yl)pyridin-2-yl)amino 4-(2-(4-yl)pyrimidin-4-yl)phenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide
[0478] To a solution of Example 17I (346 mg, 0.52 mmol) in dichloromethane (10 mL) was added hydrochloric acid (4 N in 1,4-dioxane, 6.6 mL). The reaction mixture was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and purified by silica gel column chromatography using dichloromethane and methanol (7 N ammonia in methanol was added) to give the title compound. LC / MS (ESI+): m / z 560.3 (M+H) + .
[0479] Example 17K
[0480] 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl) phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-fluorophenyl}ethyl]-1,2,4-oxadiazole 5-Diazolecarboxamide
[0481] To a solution of Example 17J (80 mg, 0.14 mmol) in N,N dimethylformamide (1 mL) was added Example 1J (56 mg, 0.16 mmol), potassium iodide (119 mg, 0.72 mmol) and N,N-diisopropylethylamine (50 μL, 0.29 mmol). The mixture was stirred at 80 °C for 2 hours. The mixture was cooled to ambient temperature, filtered, and the filtrate was directly subjected to reverse phase preparative HPLC to isolate the title compound (Phenomenex NX C18 column, 30×250 mm×5 μm, 0.1% ammonium hydroxide in water and acetonitrile as mobile phase). 1 H NMR (500 MHz, dimethyl sulfoxide-d6): δ ppm 10.30 (s, 1H), 9.98 (s, 1H), 9.86 (d, J = 7.8 Hz, 1H), 8.66 (s, 1H), 8.00 (s, 1H), 7.94 (d, J = 2.9 Hz, 1H), 7.78 (dd, J = 8.1, 1.7 Hz, 1H), 7.71 (dd, J = 11.5, 1.7 Hz, 1H), 7.66–7.57 (m, 2H), 7.37 (dd, J = 9.3, 2.9 Hz, 1H), 7.21 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 5.34 (p, J = 7.2 Hz, 1H), 3.8 0(s,1H),3.69(t,J=6.7Hz,2H),3.15(d,J=11.3Hz,1H),2.93(dd,J=10.6Hz,1H),2.79(d,J=10.4Hz,1H),2.71(dd,J=7.7,7.7Hz,2H),2.66 –2.59(m,2H),2.55–2.42(m,2H),2.38(d,J=10.9Hz,1H),2.31–2.20(m,2H),1.49(d,J=7.0Hz,3H),1.30(s,9H),0.93(d,J=6.3Hz,3H)ppm. MS(ESI)m / z 776.4(M+H) + .
[0482] generally
[0483] BTK screening
[0484] Btk kinase activity was measured in vitro using an electrophoretic mobility shift assay (MSA). The ability of Btk to phosphorylate a fluorescent peptide substrate (FAM-GEEPLYWSFPAKKK-NH2) was measured. The kinase reaction was assembled in a 384-well plate with a total volume of 25 μL per well. The following items were added to each well: compound buffer (or control); enzyme buffer; and substrate buffer, as further described below.
[0485] Specifically, the following items were added: (1) compound buffer or control: 5 μL of 5X compound buffer [(5X compound buffer consists of: 1X master buffer, X μM test compound in 5% dimethyl sulfoxide; (2X master buffer consists of: 200 mM HEPES, pH 7.5, 0.2% BSA and 0.02% Triton X-100)]; and (2) enzyme buffer: 10 μL of 2.5X enzyme buffer (1X master buffer, 12.5 mM MgCl2, 2.5 mM DTT, 25 μM sodium orthovanadate, 25 μM β-glycerophosphate and 1.25 nM BTK enzyme). Human BTK enzyme Nanosyn-293 HEK, wild type, purchased from Nanosyn, Santa Clara, CA). The enzyme and compound were pre-incubated for 15 minutes. In addition, the following items were added: (3) Substrate buffer: 10 μL of 2.5X substrate buffer (1X master buffer, 50 μM ATP, and 2.5 μM peptide substrate FAM). Each plate was incubated at 25°C for 3 hours. The reaction was terminated by adding the following items to each well: 45 μL of 1.55X stop buffer (1X master buffer and 31 mM EDTA). The final reaction mixture was as follows: 100 mM HEPES, pH 7.5; 0.1% BSA; 0.01% Triton X-100; 1 mM DTT; 5 mM MgCl2; 10 μM sodium orthovanadate; 10 μM β-glycerophosphate; 50 μM ATP; 1% dimethyl sulfoxide (from compound); 1 μM fluorescent peptide substrate and 0.5 nM BTK enzyme.
[0486] Use 12 channels The terminated reactions were analyzed using a 3000 microfluidic detection instrument (purchased from Caliper Life Sciences, Waltham, MA). Enzymatic phosphorylation of the peptide results in a change in net charge, which enables electrophoretic separation of the product from the substrate peptide. Two fluorescent peaks are observed as the substrate and product peptides separate. The change in the relative fluorescence intensity of the substrate and product peaks is a measured parameter that reflects enzyme activity. In the presence of an active compound, the ratio between product and substrate is altered. The signal for the product decreases, while the signal for the substrate increases. Capillary electropherograms (RDA acquisition files) were analyzed using HTS Well Analyzer software (purchased from Caliper LifeSciences, Waltham, MA).
[0487] The activity in each sample was determined as the ratio of product to total (PSR): P / (S+P), where P is the peak height of the product peptide and S is the peak height of the substrate peptide. For each compound, the enzyme activity was measured at different concentrations (12 concentrations of compounds, separated by 3-fold dilution intervals). Negative control samples (0% inhibition in the absence of active compounds) and positive control samples (100% inhibition in the presence of 20mM EDTA) were assembled in four replicates and used to calculate the % inhibition value of each active compound at each concentration. The inhibition percentage (Pinh) was determined using the following equation: Pinh = (PSR0%-PSRinh) / (PSR0%-PSR100%)*100, where PSRinh is the product sum ratio in the presence of inhibitors, PSR0% is the average product sum ratio in the absence of active compounds, and PSR100% is the average product sum ratio in 100% inhibition control samples.
[0488] IC of active compounds 50 Values are obtained by using The inhibition curves (Pinh vs. inhibitor concentration) were fitted to a 4-parameter sigmoidal dose-response model using IDBS 4 software (IDBS, Boston, MA). 50 The values reported in Table 2 are for BTK IC 50 (nM) column.
[0489] Cereblon binding assay
[0490] Use with Cereblon The Human Cereblon binding kit (PerkinElmer, Waltham, MA) was used for in vitro measurements according to the manufacturer's protocol ("Alpha" refers to the amplified luminescence proximity homogeneous assay). In this assay, donor beads and acceptor beads are brought into proximity by ligand binding to the CRBN protein. Excitation of the donor beads causes the release of singlet oxygen, which triggers a cascade of energy transfer reactions to the acceptor beads, resulting in a spike in light emission at 615 nm.
[0491] Specifically, nickel chelate acceptor beads (PerkinElmer AL108M) were used to capture 6XHIS-labeled CRBN proteins, and streptavidin-coated donor beads (PerkinElmer 6760002) were used to capture 50 nM biotinylated ligands. Each well included the following: sample or control; HIS-labeled CRBN protein; biotinylated ligand; nickel chelate acceptor beads; and streptavidin donor beads.
[0492] Competition assay: Using a Labcyte Echo acoustic dispenser, test compounds in 100% dimethyl sulfoxide were plated onto white low-volume 384-well plates (PerkinElmer Proxiplate 384 plus # 6008289) with an 11-point dose curve and a 3-fold dilution scheme. After adding 10 μL of a measurement mixture containing a His-tagged Cereblon / DDB1 complex and 50 μM biotin-tagged ligand in a buffer (buffer: 10 mM HEPES pH 7.4, 150 mM NaCl, 0.05% Tween-20 and 10 mM DTT), this produced a 10 μM top dose (starting concentration) and a 0.1% DMSO final concentration. The plate was incubated at room temperature for 30 minutes.
[0493] Detection: Add 10 μL of detection reagent containing nickel chelate acceptor beads and streptavidin donor beads (PerkinElmer 6760002) under low light conditions, resulting in a final concentration of 20 μg / ml. Incubate the plate for 1 hour and TM Envision TM The plate was read on a plate reader (680 nm excitation and 570 nM emission settings). The IC of each compound was determined by calculating the percentage inhibition of the no drug and no protein controls. 50 , and the Cheng-Prusoff transformation was used to calculate the K of each compound. i By K i Determine IC 50 Value. IC 50 The values reported in Table 2 are for CRBN IC 50 (nM) column.
[0494] Determination of Bik protein in human whole blood based on MSD ELISA
[0495] Btk protein degradation was tested using the Meso Scale Discovery-ELISA system (MSD-ELISA): (1) test compounds were added to human whole blood; (2) human whole blood cells treated with the test compounds were lysed; (3) the lysed cells were treated with capture antibody (antibody to Btk); (4) the lysed cells were treated with anti-mouse primary antibody to Btk; and (5) the lysed cells were treated with anti-mouse antibody (labeled).
[0496] Specifically, approximately 80 μl of fresh human whole blood from a healthy donor was transferred to each well of a 96-well V-bottom plate (Costar, catalog number 3894). TM Using a D300e digital dispenser (Tecan), compounds were added in duplicate at 1:4 serial dilutions [(8 pt assay) in DMSO solution (final 0.2%), starting at 3 μM top concentration]. Afterwards, the plates were placed in a 37°C incubator and incubated for 6 hours.
[0497] At the end of the incubation, 80 μl of 2X CST lysis buffer (Cell Signaling Technology, catalog number 9803) prepared from 10X stock solution was added per well to lyse the blood. The plate was then sealed with a plate sealer and the samples were frozen at -80°C overnight.
[0498] MSD-ELISA was used to measure the total amount of BTK protein retained in the blood sample after compound treatment. After thawing the frozen plate, the blood lysate was thoroughly mixed and transferred to a small spot high binding MSD plate (Meso Scale Discovery, catalog number L45XB-3) and coated with capture antibody, rabbit anti-human BTK (D3H5) (Cell Signaling Technology, catalog number 8547CF). Thereafter, the primary detection antibody, mouse anti-human BTK monoclonal antibody (BD Biosciences, catalog number 611117) and the secondary detection antibody, anti-mouse sulfonyl tag (Meso Scale Discovery, catalog number R32AC-1) were added. The assay plate was read on the MSD S600 plate reader by adding 2X MSD read buffer (Meso Scale Discovery, R92TC-1). All reagent transfers, including blood lysis, were performed using the Biomed i7 liquid handler. From the dose response curve, DC was calculated by averaging the data from repeated experiments. 50 Values were calculated and curve fitting was performed by nonlinear regression using GraphPad Prism. 50The values reported in Table 2 are hWB BTK DC 50 (nM) column. max The values represent the maximum amount of BTK degradation observed upon compound treatment compared to DMSO-only treated samples. The dMax (%) values are reported in the hWB BTK dMax (%) column of Table 2.
[0499] Mouse bone marrow assay
[0500] Female C57BL / 6J mice (Jackson Laboratories) were used for this study. Compounds or vehicle / controls were prepared with EtOH, PEG-400, Phosal 53MCT (10:30:60, v / v). Four mice were tested for each compound or vehicle / control. On day 1, mice were administered a single dose of dose A. On day 2 (after 24 hours), tissue (bone marrow) was collected from one hind leg of each mouse.
[0501] BTK degradation in mouse bone marrow was determined using an MSD (Meso Scale Discovery) ELISA (enzyme-linked immunosorbent assay)-based assay. The following materials and equipment were used: 10% NP40 solution (non-ionic polyoxyethylene surfactant, ThermoFisher, catalog number 28324); protease inhibitor mini tablets (Roche, catalog number 05892970001); PhosphoSTOP TM Tablets (Roche, catalog number 04906837001); Pierce TM BCA Protein Assay Kit (Thermofisher, Cat. No. 23225); with 2.8 mm beads 2mL lysis tube (VWR, catalog number 10032-756); Bertin Cooling system; 96-well MSD streptavidin pre-coated plates (MSD, catalog number L15SA-1); MSD Blocker A (MSD, catalog number R93BA-4); Capture antibody, biotinylated BTK mAb (BD Biosciences, catalog number 624008, custom order); Primary detection antibody, BTK RpAb (rabbit polyclonal antibody, CST, catalog number 8547S, clone D3H5); Secondary detection antibody, anti-rabbit Sulfo-tag (MSD, catalog number R32AB-1); Read buffer, 4X (MSD, catalog number R92TC-1); Recombinant BTK protein (Thermofisher, catalog number PR5442A); MSD Tris WashBuffer (10x) (MSD, catalog number R61TX-1); PBS (phosphate buffered saline); deionized water (diH2O); lysis buffer [0.2% NP40 in PBS + protease inhibitor tablets (1 tablet / 10 mL) + PhosphoSTOP tablets (1 tablet / 10 mL)]; 3% MSD blocker A [MSD blocker A+450 mL diH2O+50 mL]; and 10x MSD Tris wash buffer.
[0502] program
[0503] Sample processing for PD determination
[0504] Mouse bone marrow lysate preparation
[0505] Prepare lysis buffer [(PBS + 0.2% NP40 + PI (protease inhibitor) + PhosphoSTOP)] and place on ice until it is completely cooled. Add ice-cold lysis buffer (300 μl) to the tube. Transfer the sample tube to The lysates were centrifuged at 14,000 rpm for 20 min at 4°C.
[0506] Protein estimation (BCA)
[0507] Using Pierce TM Protein concentration was determined using the BCA protein assay kit following the manufacturer's recommended protocol. A working solution of protein standardization was prepared using 30 μg of protein per sample lysate for the assay.
[0508] Standard curve sample preparation
[0509] A 300 ng / ml working stock solution of recombinant BTK protein in lysis buffer was prepared, and samples were serially diluted in 3-fold dilutions (10 point assay, highest concentration was 300 ng / mL, and lowest concentration was 0.015 ng / mL).
[0510] Performing MSD assays
[0511] Day 1
[0512] MSD plate coating: Prepare a coating antibody (biotinylated BTK mAb) stock solution at 1 μg / mL in PBS buffer. Add 50 μL / well of capture antibody (biotinylated BTK mAb) solution and gently shake the plate at ambient temperature for two hours. Wash the plate 3 times (300 μL / well) with 1X MSD Tris wash buffer in a plate washer and block the plate with 3% MSD blocker A (150 μL / well). Incubate the plate for another 1-2 hours at ambient temperature with gentle shaking. Using a plate washer, wash the plate 3 times with 1X MSD wash buffer. Add bone marrow lysate (30 μg) to the plate in a final volume of 50 μL / well. Add serially diluted standard samples to the same plate in a final volume of 50 μL / well. Incubate the plate overnight at 4°C with gentle shaking.
[0513] Day 2
[0514] Using a plate washer, wash the plate three times with 1X MSD wash buffer (prepared from 10X concentration buffer). Add primary detection antibody (BTK RpAb; 1:1000 dilution in 1% MSD blocker A) at 50 μL / well. Incubate the plate at ambient temperature with gentle shaking for two hours. Using a plate washer, wash the plate three times with 1X MSD wash buffer. Add anti-rabbit sulfo tag secondary antibody (50 μl / well) diluted 1:500 in 1% MSD blocker A, and incubate the plate at ambient temperature for one to two hours. Using plate washing, wash the plate three times with 1X MSD tris wash buffer. Add MSD read buffer (150 μL) (1X) and read the plate with an MSD machine. Generate a standard curve, and use the absolute BTK amount to calculate the % of BTK remaining in the vehicle and treatment samples. The % of Btk remaining in the sample is reported in Table 2.
[0515] The measurement results of Examples 1-19 are shown in the "Mouse Bone Marrow (%) column" of Table 2.
[0516] Table 2
[0517]
[0518] Nd = Undetermined
[0519] Compound 1 (Example 1) controls BTK in C57BL / 6 mice C481S Circulating leukemic burden in mutant TCL1-driven CLL
[0520] Tumor cell formation
[0521] Eμ-TCL1 CLL transgenic mice (Crogen Pharmaceuticals LLC) were cross-linked with BTK C481S Knock-in mice (AbbVie) were crossed to generate BTK C481S Mutant Eμ-TCL1 transgenic mice. C481S Leukemic splenocytes from Eμ-TCL1 transgenic mice (passage 1) were intravenously transplanted into C57BL / 6 mice, resulting in the development of CLL in peripheral blood and spleen. When the circulating CLL load (CD5+CD19+ cells, as described below) in recipient mice reached more than 90%, their splenocytes containing high CLL load (passage 2) were cryopreserved and used for CLL efficacy studies.
[0522] Animal Husbandry
[0523] Mouse tumor efficacy studies were conducted in accordance with AbbVie's Institutional Animal Care and Use Committee and National Institutes of Health guidelines for the care and use of laboratory animals in an animal facility in South San Francisco, Calif. C57BL / 6 mice were obtained from Jackson Laboratories and housed in groups of 5 per cage on a 14-hour light: 10-hour dark schedule.
[0524] Tumor implantation and animal treatment
[0525] The second generation Eμ-TCL1 BTK containing high CLL burden C481S Splenocytes were thawed in cold Hanks balanced salt solution (HBSS), washed and filtered through a 70 μM filter. 10 × 10 6 Splenocytes per mouse were injected intravenously into the tail vein of 8-10 week old female C57BL / 6 mice to establish CLL.
[0526] To determine absolute / total leukocyte counts, use Genesis TM Complete blood counts were determined for each mouse using a veterinary hematology analyzer (Oxford Science Inc.).
[0527] Flow cytometry
[0528] Cells isolated from mouse peripheral blood mononuclear cells (PMBC) were collected to determine antigen expression. PMBC were stained with antibodies specific for mouse CD5, CD19, and CD45 (cells expressing CD5+CD19+ are often present in mouse B cell leukemia and are considered CLL cells). Cells were gated on CD45+ and the percentage of CD5+CD19+ cells from this subset was calculated. TM Flow cytometry was performed on an X-20 cell analyzer (BD Biosciences).
[0529] Whole blood was collected weekly via submandibular cheek bleeds after tumor implantation. The absolute / total leukocyte counts were multiplied by the number of cells with the immunophenotype CD19. + CD5 + The circulating leukemic burden was calculated by the percentage of leukocytes in the blood.
[0530] Starting from day 9 after inoculation, mice were weighed, bled, and randomly divided into five groups of N = 10. The average circulating CD19 + CD5 + CLL cell count was 1,525 / μL. Compound 1 (Example 1) at various concentrations was formulated in a vehicle containing 10% ethanol, 30% PEG-400, and 60% Phosal-50 MCT. The vehicle contained 10% ethanol, 30% PEG-400, and 60% Phosal-50 MCT.
[0531] CLL counts were randomized two days after and mice were treated once daily (QD) for 19 days: Group 1: Vehicle; Group 2: Compound 1 Dose 1; Group 3: Compound 1 Dose 2; Group 4: Compound 1 Dose 3; Group 5: Compound 1 Dose 4.
[0532] As shown in FIG1 , compound 1 (Example 1) controls the expression of BTK in C57BL / 6 mice in a dose-dependent manner. C481S Circulating leukemic burden of mutant TCL1 driven CLL. The y-axis shows the number of CLL cells (CD19+CD5+) per μL of mouse PMBC. Complete CLL burden control (i.e., no increase from initial tumor burden) was achieved by compound 1 at doses 3 and 4.
[0533] All publications and patents mentioned herein are hereby incorporated by reference in their entirety to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
[0534] It should be understood that the foregoing detailed description and the accompanying examples are exemplary only and should not be taken as limiting the scope of the present disclosure, which is defined by the appended claims and their equivalents.
Claims
1. A compound of formula (I): in R 1 is selected from the group consisting of hydrogen, C1-C3 alkyl, CN, C1-C3 haloalkyl, halogen, CH2OCH3, CH2OH and CH2CN; R 2 and R 3 each independently selected from the group consisting of: hydrogen and halogen; R 4a and R 4b Each independently selected from the group consisting of hydrogen, C1-C3 alkyl and CH2OCH3; R 5 is selected from the group consisting of hydrogen, halogen and C1-C3 alkyl; or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, wherein R 4a is H and R 4b is methyl, or a pharmaceutically acceptable salt thereof.
3. A compound according to any one of claims 1 to 2, wherein R 1 is methyl or a pharmaceutically acceptable salt thereof.
4. A compound according to any one of claims 1 to 3, wherein R 2 is hydrogen or a pharmaceutically acceptable salt thereof.
5. A compound according to any one of claims 1 to 4, wherein R 3 is hydrogen or a pharmaceutically acceptable salt thereof.
6. A compound according to any one of claims 1 to 5, wherein R 5 is hydrogen or a pharmaceutically acceptable salt thereof.
7. A compound, which is , or a pharmaceutically acceptable salt thereof.
8. A compound which is a pharmaceutically acceptable salt of:
9. A compound, which is 10. The compound according to claim 1, selected from the group consisting of: 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)-3-fluorophenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)-3-fluorophenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)-3-fluorophenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-ethylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2,2-dimethylpiperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-3-fluoro-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-3-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-{(1R)-1-[4-(6-{[5-(4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}piperazin-1-yl)pyridin-2-yl]amino}pyrimidin-4-yl)-5-fluoro-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-(propan-2-yl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{2-chloro-4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]phenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2R)-4-{2-[4-(2,4-dioxo-1,3-oxadiazin-1-yl)phenyl]ethyl}-2-(methoxymethyl)piperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-methylphenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-(trifluoromethyl)phenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; and 3-tert-butyl-N-[(1R)-1-{4-[6-({5-[(2S)-4-{2-[4-(2,4-dioxo-1,3-diazin-1-yl)phenyl]ethyl}-2-methylpiperazin-1-yl]pyridin-2-yl}amino)pyrimidin-4-yl]-2-fluorophenyl}ethyl]-1,2,4-oxadiazole-5-carboxamide; or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.
